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The  aim  of  this  study was  to  isolate  and  characterise  novel  anti‐inflammatory  compounds  from 
native  Australian  plants  which  were  important  to  the  D’harawal  Aboriginal  people  for  anti‐
inflammatory  and  related  activities.  A  total  of  thirty  two  plants  were  screened  for  their  anti‐
inflammatory and neuroprotective activity. 
In chapter 2, ethanolic extracts of seventeen Eucalyptus spp.  (Myrtaceae) were screened  for  their 
nitric oxide  (NO) and  tumour necrosis  factor‐α  (TNF‐α) downregulation activity and cytotoxicity  in 
lipopolysaccharide  (LPS) and  interferon‐γ  (IFN‐γ) activated RAW 264.7 macrophages. Extracts  from 
seven Eucalyptus spp. demonstrated strong activity with IC50 values between 7.58 ‐ 19.77 µg/mL for 
NO  inhibition  and  IC50  values  for  suppression  of  TNF‐α  production  were  between  2.06  –  19.02 
µg/mL. These extracts also showed a wide  range of cytotoxicity with LC50 values between 22.34 – 
236.5  µg/mL. 
In chapter 3,  two of  the highly active Eucalyptus  spp.  (Myrtaceae), E. viminalis and E. bosistoana 
were  sequentially  extracted  and  screened  to  find  out  the most  active  extracts which were  then 
fractionated to identify bioactive compounds. From E. viminalis a new chromone (compound 1) has 
been  identified  together  with  two  known  compounds  8‐β‐C‐glucopyranosyl‐5,7‐dihydroxy‐2‐
isobutylchromone  and  globuluside.    The  anti‐inflammatory  and  cytotoxic  activities  of  all  three 
compounds were evaluated  against RAW 264.7 macrophage  and N11 microglial  cell  line.  In RAW 
264.7 macrophage, the IC50 values for NO down regulation were 44.0, 47.0 and 37.6 µg/mL whereas 
the  IC50  of  TNF‐α  suppression  were  41.0,  38.3  and  43.2  µg/mL  for  compound  1,  8‐β‐C‐
glucopyranosyl‐5,7‐dihydroxy‐2‐isobutylchromone  and globuluside  respectively.  In N11 microglia, 




hydrolyzed  product  of  compound  1  was  also  tested  for  its  anti‐inflammatory  activity.  The  NO 
inhibitory IC50 values were 18.7 and 10.2 µg/mL and TNF‐α inhibitory IC50 values were 21.5 and 17.0 
µg/mL for oleuropeic acid against RAW 264.7 macrophage and N11 microglial cell line respectively. 
From  E.  bosistoana  (chapter  3a)  one  known metabolite,  4‐coumaroylquinic  acid  was  identified 
whose anti‐inflammatory and cytotoxic activities were evaluated in RAW 264.7 macrophage and N11 
microglial cell line as well. In RAW 264.7 macrophages the compound exhibited IC50 values of 95.74 
and 52.56 µg/mL  for NO and TNF‐α  inhibition  respectively. Whereas  in N11 microglia  the NO and 
TNF‐α  inhibitory  IC50 values were 44.31 and 35.50 µg/mL.  In both cell  line the compound was non‐
toxic up to the highest concentration (36 µg/mL) tested.  
In  chapter 4, ethanolic extracts of  fifteen plant  species  from 8 different  families and 11 different 
genera were screened  for  their NO and TNF‐α downregulation activity and cytotoxicity  in LPS and 









the  sequential  extracts  were  screened  for  their  anti‐inflammatory  activity  to  identify  the  most 
potent one, which was then purified using HPLC. From this plant, two known flavonoids 3, 3', 4', 5, 7‐
pentahydroxyflavan and 3, 3’, 5, 5’, 7‐ pentahydroxyflavan were  identified along with one known 
triterpenoid  betulinic  acid.  The  anti‐inflammatory  activities  as  well  as  cytotoxicity  of  all  three 
compounds were evaluated  in RAW 264.7 macrophage and N11 microglial cell  line.  In RAW 264.7 
macrophage, the IC50 values for NO down regulation were 72.81, 39.69 and 2.73 µg/mL whereas the 
IC50  of  TNF‐α  suppression  were  58.88,  80.70  and  4.11  µg/mL  for  3,  3',  4',  5,  7‐





polar  solvents  and  the  sequential  extracts were  screened  for  their  anti‐inflammatory  activity  to 
identify  the  most  potent  one,  which  was  then  purified  using  HPLC.  From  this  plant,  two  new 
compounds  compound  6.1  and  6.4  were  identified  along  with  three  known  compounds 
tetragocarbone B  (compound 6.2),   sideroxylin  (compound 6.3) and  lumaflavanone A  (compound 
6.5). The anti‐inflammatory and  cytotoxic activities of all  five  compounds were evaluated  in RAW 
264.7 macrophage and N11 microglial cell  line.  In RAW 264.7 macrophage,  the  IC50 values  for NO 
down  regulation  were  3.91,  35.15,  2.76,  29.42  and  7.84  µg/mL  whereas  the  IC50  of  TNF‐α 
suppression were 16.90, 32.12, 20.80, 37.57 and 33.35 µg/mL  for compound 6.1, 6.2, 6.3, 6.4 and 
6.5  respectively.  In N11 microglia,  the  IC50 values  for NO down  regulation were 4.52, 21.17, 3.87, 
39.64 and 4.51 µg/mL whereas the IC50 of TNF‐α suppression were 6.50, 27.01, 13.66, 33.06 and 5.46 
µg/mL for compound 6.1, 6.2, 6.3, 6.4 and 6.5 respectively.  
In  chapter  7,  Baeckea  ramosissima  subsp.  ramosissima  and  B.  imbricata  leaves were  extracted 
sequentially with low to high polar solvents and the sequential extracts were screened for their anti‐
inflammatory activity  to  identify  the most potent one. Sequential EtOAc extract  from both plants 
showed highest anti‐inflammatory activity for NO inhibition (IC50 = 9.33 and 8.98 μg/mL for Baeckea 
ramosissima subsp. ramosissima and B.  imbricata respectively)  in LPS +  IFN‐γ activated 264.7 RAW 



































Inflammation  is  an  important  biological  process  for  maintaining  the  body’s  homeostasis.  It  is 
necessary  for protecting  the body  against pathogenic organisms  as well  as  chemical  and physical 
stimuli  and  initiating  wound  healing  mechanisms  to  repair  damaged  tissue  [1].  But  when 
uncontrolled,  inflammation  plays  a  role  in  the  development  and  progression  of  human  diseases 
including asthma, rheumatoid arthritis, inflammatory bowel disease, Crohn’s disease and tendonitis. 
Moreover,  chronic  inflammatory  response  is  a major  driving  force  for  the progression of  cancer, 
atherosclerosis, diabetes, obesity and Alzheimer’s disease. In this sense, inflammation can be viewed 
as a double‐edged sword [1,2]. 
Currently,  both  steroidal  and  non‐steroidal  anti‐inflammatory  drugs  (NSAIDs)  are  used  to  treat 
inflammation. Steroids have an obvious role in the treatment of inflammatory diseases, but can only 
be used over short periods due to the onset of a number of adverse effects associated with chronic 
use,  except  in  very  serious  cases  where  the  benefits  outweigh  the  risks.  On  the  other  hand, 
prolonged  use  of  NSAIDs  is  also  associated  with  severe  side  effects,  notably  gastrointestinal 
haemorrhage  [3‐5]. The newer selective cyclooxygenase‐2  (COX‐2)  inhibitors originally designed  to 
overcome such issues also do not seem to be free of risk [4,6]. Consequently, there is some urgency 
for the discovery of new anti‐inflammatory compounds with less or no side effects [1,5].  
Plants were  the  first  source of  remedies  in  the history of mankind. Plants or different plant parts 
were  used  as  drugs  against  all  types  of  treatment  in  all  cultures  and  through  all  ages  [1].  The 
anticancer vinblastine and vincristine from Catharanthus roseus and paclitaxel from Taxus brevifolia, 
the  antimalarial  quinine  from  Cinchona  species,  the  antiglaucoma  pilocarpine  from  Pilocarpus 
jaborandi,  the  analgesics  morphine  and  its  derivative  codeine  from  Papaver  somniferum,  the 
spasmolytic  and  cold medicine  atropine  from  Atropa  belladonna  and Hyoscyamus  niger  and  the 
cardiac glycosides  (e.g. digoxin)  for the treatment of congestive heart failure from Digitalis species 
all  share  two  important  characteristics  in  common:  they  are  the  keystones  of  modern 




to meet  the  primary  healthcare  needs  of  60‐90%  of  the  population  [1,10,11].  In  the  developed 
world, a growing awareness of the potency and side effects of synthetic drugs, has coincided with a 
shift  towards  people  seeking  natural  product  remedies  [11].  The  term,  ‘complementary  and 
alternative medicine’ (CAM) encompasses a broad range of ancient to modern day treatment where 
complementary  interventions  are  used  together  with  conventional  treatment  and  alternative 
interventions  are  used  instead  of  conventional  medicine  [12].  In  Australia,  Europe  and  North 
America,  the  usage  of  CAM  is  increasing  [10].  This  does  not  infer  however,  that  whole  plant 
remedies are devoid of side effects and hence it is important the safety and efficacy of such products 
are validated using rigorous scientific methodologies. 
World  Health  Organization  (WHO)  rephrases  traditional  medicine  (TM)  and  complementary 






the maintenance of health  as well  as  in  the prevention, diagnosis,  improvement or  treatment of 
physical  and mental  illness,  CM:  The  terms  “complementary medicine”  or  “alternative medicine” 
refer  to  a broad  set of health  care practices  that  are not part of  that  country’s own  tradition or 
conventional medicine and are not fully integrated  into the dominant health‐care system. They are 
























tissue homeostasis. Therefore,  inflammation  is considered as an  ‘adaptive response’  that operates 






fibroblasts  respond  to  inflammatory  cues  as  well  as  further  mediating  the  process.  Different 
inflammatory pathways are  initiated depending on  the nature of  the stimulant. Bacterial  infection 
causes  activation  of  pathogen  specific  receptors.  Consequently,  inflammatory  mediators  like 
cytokines (e.g. tumor necrosis factor (TNF), interlukin‐1 (IL‐1) and interlukin‐6 (IL‐6)) and chemokines 









Pattern  recognition  receptors  (PRRs)  (e.g. Toll‐like  receptors  (TLRs), C‐type  lectin  receptors  (CLRs), 
RIG‐1‐like receptors (RLRs) and NOD‐like receptors (NLRs)) are the specific transmembrane receptors 
expressed  by  both  innate  and  adaptive  immune  cells.  These  receptors  first  recognize  the 
inflammatory  stimuli by  recognizing  structures  conserved  in microbes,  called pathogen‐associated 
molecular  patterns  (PAMPs)  [24]. As  these  receptors  interact with  the  appropriate  stimuli,  signal 
transduction  to  the nucleus  takes place  resulting  in activation of a  selective  set of genes  through 











Nitric oxide  (NO), a  toxic atmospheric gas,  is also generated by mammalian cells.    Its multitude of 





































in  cells  and  synthesise  NO  in  response  to  an  increase  in  calcium  or  in  some  cases  to  calcium 
independent stimuli such as shear stress. The third  isoform  iNOS  is constitutively expressed only  in 
some tissues such as lung epithelium and is typically rapidly induced and upregulated in response to 
inflammatory or pro‐inflammatory mediators [5,27,28].  
Macrophage  activation  by  lipopolysaccharides  (LPS),  a  major  component  (endotoxin)  of  gram‐
negative bacteria cell walls,  results  in  the  release of several  inflammatory mediators  including NO 
[29]. Upon induction by certain inflammatory stimuli, e.g. bacterial lipopolysaccharide (LPS), the NF‐
κB  signal  pathway  is  activated,  regulating  the  expression  of  a wide  variety  of  genes  involved  in 
inflammatory responses, e.g. the cytokines TNF‐α and IL‐1β, and the enzymes  inducible nitric oxide 
synthase  (iNOS)  and  cyclooxygenase‐2  (COX‐2). The enzyme  iNOS  catalyzes  the  conversion of  the 
amino acid L‐arginine to NO, which is cytotoxic and cytostatic. Therefore, inhibition of NO production 
(through iNOS) is a major target for anti‐inflammatory compound development. Many studies have 





Cytokines  are  secreted, highly  localized,  low molecular weight  proteins  (molecular weight  ranges 
from 6 to 70 kDa)  that regulate  the  immune response and  in  large part determine  the  form of an 




are  uniquely  capable  of  promoting  the  cellular  infiltrate  and  damage  to  resident  tissue  that  are 
characteristic of inflammation. These cytokines include tumour necrosis factor (TNF), interleukin (IL) 




MAPK  and PKC)  that,  in  turn,  regulate  the  expression of many  target  genes  indispensable  to  the 
maintenance of the inflammatory state. For instance, cytokines may be responsible for the induction 
of  several  enzymes  (e.g.  iNOS  and  COX‐2),  receptors  (PAF  receptor,  IL‐2  receptor)  and  adhesion 
molecules  (E‐selectin,  α‐  and  β‐integrins,  ICAM‐1, VCAM‐1). Besides mediating  inflammation  they 
also  contribute  to  a  chemical  signalling  language  that  regulates  development,  tissue  repair, 
hemopoiesis and other specific and nonspecific  immune responses  [33].  It has been observed that 
several  compounds  are  able  to  decrease  the  expression  of  different  pro‐inflammatory 
cytokines/chemokines  such  as  TNF‐α,  IL‐1β,  IL‐6,  IL‐8,  MCP‐1  in  LPS‐activated  mouse  primary 





Nuclear  factor‐B  (NF‐B)  is a  family of dimeric proteins  that  regulates  the expression of multiple 
immune  and  inflammatory  genes  [36‐38].  It  is  present  in  the  cytoplasm  in  an  inactive  form 
complexed  to  an  inhibitory  protein,  I‐B. Many  extracellular  stimuli,  including  viruses,  oxidants, 
inflammatory cytokines and immune stimuli, activate NF‐B. Once activated, it binds to recognition 
elements  in  the  promoter  regions  of  inflammatory  and  immune  genes,  such  as  proinflammatory 
cytokines, chemokines,  inflammatory enzymes and adhesion molecules. This activation leads to the 
co‐ordinated expression of  inflammatory response and plays a key regulatory role  in host defence 
[36].  The  dysregulation  of  NF‐B  is  associated  with  many  disease  states  such  as  AIDS, 
atherosclerosis,  asthma,  arthritis,  cancer,  diabetes,  inflammatory  bowel  disease,  muscular 
dystrophy, stroke and viral infections. Recent evidence also suggests that the dysfunction of NF‐B is 
a major mediator of some human genetic disorders  [38]. NF‐B  is  therefore an obvious  target  for 
new  types  of  anti‐inflammatory  treatment  [37].  Anti‐NF‐B  therapy  provides  the  means  to 
simultaneously  inhibit expression of numerous  inflammatory mediators,  including TNF‐ and  IL‐1. 
Recent  discoveries  of  the  critical  components  (e.g.  I‐B  kinases)  of  the NF‐B  signalling  pathway 
have  revolutionized  the  field and offered  the opportunity  to  start a  systematic  search  for  specific 











effects of endotoxin.  In most cells NF‐B  is associated  in the cytoplasm with  its  inhibitory subunit, 
inhibitory kappa B (I‐B), which prevents NF‐B from translocating into the nucleus. Multiple stimuli, 
including LPS, induce the phosphorylation and degradation of I‐B , allowing NF‐B to translocate to 







since  it  is normally  terminated once  the potential danger  is eradicated. Usually  the  inflammatory 
response  reverts  to  the homeostatic  state quite  rapidly, a highly  regulated process  known as  the 
resolution of  inflammation [23]. The resolution of  inflammation  is dominated by a number of anti‐
inflammatory mediators such as IL‐10, TNF‐ and glucocorticoids and it also involves the recruitment 
of monocytes  for  the  clearance of  cell debris  [41].  If  the  resolution of  inflammation  fails  for  any 
reason, the acute inflammatory response turns chronic. Chronic inflammation has been a subject of 
extensive  studies  over  many  decades  not  only  for  the  growing  burdens  of  the  associated 





Chronic  inflammation  is a major driver of pathogenesis and  is associated with a number of chronic 




insulin  resistance.  Rheumatoid  arthritis  is  another  chronic  inflammatory  disorder  in  which,  the 




Inflammation  in  asthma  and  allergies  are  caused  by  dysregulated  interactions  between mucosal 
epithelia and innate immune cells [23]. Further studies suggested that apart from innate  immunity, 
cells of adaptive  immunity  such as CD4 T helper 2  (Th2)  cells as well as Th2 associated  cytokines 
were found to be strongly linked to asthma [44]. Even though genetic predisposition to asthma has 
been  reported  for  years,  recent genome‐wide  studies  suggest  that  the hereditary  contribution  to 
asthma  is  relatively  small  [45].  Other  studies  demonstrated  that  several  viral  upper  respiratory 
9
infections  caused  by  environmental  factors,  early  in  the  life  along  with  genetic  predisposition 
increases the risks for asthma [46]. 
Over  the  last decades  it has become evident  that  inflammation plays  a  critical  role  in promoting 
cancer, in particular tumorigenesis (tumour formation) [23]. In addition to cancer cells, various types 
of immune cells are commonly found within tumours and an inflammatory microenvironment is also 
more  frequently  found as an essential part of all  tumours  [47,48].  It has also been demonstrated 
that the inflammatory response triggered by infection is associated with increased cancer risk [49]. 
The  pathological  hallmarks  of Alzheimer’s  disease  (AD)  in  the  brain  include  extracellular  amyloid 
plaques  comprising  aggregated,  cleaved  products  of  the  amyloid  precursor  protein  (APP)  and 
intracellular  neurofibrillary  tangles  (NFTs)  generated  by  microtubule‐binding  protein  tau 
phosphorylation [42,50]. Aggregates of A activate microglia and induce production of a number of 
inflammatory  mediators  such  as  NO,  ROS,  proinflammatory  cytokines  (e.g.  TNF‐,  IL‐,  IL‐6), 












people worldwide  use  them  regularly  [52].  Examples  of  commonly  used  NSAIDs  include  aspirin, 
ibuprofen and naproxen [7]. 
NSAIDs  inhibit cyclooxygenase (COX), the enzyme responsible for conversion of arachidonic acid to 
prostaglandins.  COX  exists  in  2  isoforms.  COX‐1  is  an  ubiquitous  constitutive  isozyme  producing 
prostaglandins responsible  for homeostatic  functions such as maintenance of GI mucosal  integrity. 
COX‐2  is  largely  a  cytokine‐induced  isozyme  producing  prostaglandins  that  mediate  pain  and 
inflammation. NSAIDs inhibit both COX‐1 and COX‐2 to varying degrees. Thus, the therapeutic effects 
of  conventional NSAIDs  are  derived  from  inhibition  of  COX‐2, while  the  adverse  effects  of  these 
agents, particularly in the upper GI tract, arise from inhibition of COX‐1 activity [53]. 
NSAIDs  use  has  been  associated  with  colonic  bleeding, iron  deficiency  anaemia, strictures, 




COX‐2  is  largely  a  cytokine‐induced  isozyme  producing  prostaglandins  that  mediate  pain  and 
inflammation [53]. Two recently developed COX‐2 inhibitors celecoxib and rofecoxib were approved 
by  the US  Food  and Drug Administration  (FDA),  as well  as  some  European  countries.  They were 













of  time) may  cause problems  including: bruising of  the  skin, weight  gain, osteoporosis, diabetes, 
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People have used plants  for healing  for  centuries.  Plant products  –  as part of  foods or botanical 
potions and powders have been used with varying success to cure and prevent diseases throughout 
history  [58]. The  strong historic bond between plants and human health began  to unveil  in 1897, 
when synthetic aspirin (acetyl salicylic acid) was introduced to the world [58]. Aspirin  is a safer and 
more  potent  synthetic  analogue  of  salicylic  acid,  an  active  ingredient  of  willow  bark  and  was 
discovered independently by residents of both the modern and old worlds as a remedy for aches and 
fevers [59]. 
Until  the  last century most medicines were derived directly  from plant or animal sources. Despite 
the  increasing  use  of  synthetic  drugs,  natural  organic  healing  materials  have  persisted  as  the 
“treatment of choice” for a multitude of health problems in populations throughout the world [60]. 
As  stated by  the  researcher Alan Harvey, “natural products continue  to provide greater structural 







various  diseases  including  inflammatory  disorders  [62].  In  recent  years,  the  search  for  new  anti‐
inflammatory and anti‐allergic agents from a  large array of medicinal plant resources is  intensifying 
[63].  In  fact,  a  variety  of  bioactive  components  have  been  shown  to  modulate  inflammatory 
responses [64]. 
The anti‐inflammatory activity of  several plant extracts and  isolated compounds has already been 











officinalis),  caper  (Capparis  sicula  Veill.  subsp.  sicula),  mallow  (Malva  sylvestris),  mint  (mentha 
aquatica) and radish (Raphanus raphanistrum) have shown to inhibit croton oil‐induced ear oedema 
in mice with the ethanolic extracts of each plant [68]. 
Treatment  of  LPS‐stimulated  macrophages  with  extracts  from  strawberry  (Fragaria  ananassa), 
loquat  (Eriobotrya  japonica), mulberry  (Morus alba) and bitter melon  juice  (Momordica charantia) 
decreased the secretion of IL‐6 and IL‐1β pro‐inflammatory cytokines and up‐regulated the secretion 
of the anti‐inflammatory cytokine IL‐10 in a prophylactic cell culture model [69].  
Various  plant  compounds  have  also  been  shown  to  exhibit  anti‐inflammatory  activity: Quercetin 
inhibits  iNOS, COX‐2 and C‐reactive protein  (CRP), and down‐regulates NF‐B and TNF‐α secretion. 





For  over  40,000  years,  Aboriginal  Australian  peoples  have  passed  down  through  oral  history, 
traditional knowledge including the preparation and uses of different medicinal plants. A number of 




plam  (Terminalia  ferdinandiana)  contains  an  extremely  rich  mixture  of  phytochemicals  and 
demonstrated a  range of  significant biological activities  in vitro,  including antioxidant activity,  the 
inhibition of COX‐2 and iNOS in LPS‐activated murine macrophages [17]. Illawara plum (Podocarpus 
elatus) extract on the other hand, has been shown to reduce the proliferation of colon cancer cells 
and  could  lead  to  provisions  for  an  alternative  chemoprevention  strategy  to  conventional 
chemotherapy  [75].  Mueller  and  co‐workers  have  identified  new  antimalarial  leads  from  the 
Australian tree Mitrephora diversifolia [76]. Methanol extracts of traditionally used Australian plants 
Eremophila maculata, Acacia auriculoformis and Acacia bivenosa exhibited antibiotic effects while 





inflammatory activities  [16].  Simpson and  co‐workers  isolated  clerodane diterpenoids  (Figure 1‐5) 
from  the  Australian  plant  Dodonaea  polyandra  and  demonstrated  anti‐inflammatory  activity  of 






An  extract  with  anti‐inflammatory  activity  has  been  obtained  from  the  seeds  of  the  Australian 










Triterpenoid  saponins  from  the  Australian  desert  tree  Acacia  victoriae  have  anti‐inflammatory 
effects by  inhibiting activation of NF‐κB,  through prevention of nuclear  localization and binding  to 
DNA  [80]. Another Australian medicinal plant Tinospora smilacina  is claimed  to possess  long chain 
unsaturated  fatty  acids  which  possess  anti‐inflammatory  properties  [81]. Meanwhile,  the  native 
Australian  fruits  Kakadu plum  (Terminalia  ferdinandiana),  Illawarra plum  (Podocarpus  elatus)  and 
Native current (Acrotriche depressa) all exhibit significant anti‐inflammatory activities [17,18]. 
In  an  anti‐inflammatory  study,  researchers  investigated  ethanolic  extracts of  13 Australian plants 
(Acacia  adsurgens,  Acacia  ancistrocarpa,  Abrus  precatorius,  Acacia  catechu,  Clematis  glycinoides, 





Biologically  active  natural  products  continue  to  be  useful  in  the  exploration  and  control  of 
intracellular  signalling  processes.  For  example,  Kwok  and  co‐researchers  demonstrated  that  a 
sesquiterpene  lactone  derived  from  the  herb  Feverfew  (Tanacetum  parthenicum)  inhibited 
proinflammatory  pathway  by  inhibiting  IB  and  thereby  preventing  NF‐B  activation  [82]. 
Polyphenols  (e.g.,  catechins,  proanthocyanidin,  resveratrol,  silymarin) which  are  a  large  family  of 
naturally occurring plant products have proved to be anti‐inflammatory. For example, catechins can 




by modulating proinflammatory gene expression  including  iNOS and several cytokines.  (Figure 1‐7) 
For example, quercetin can  inhibit PLA2. Another  flavonoid, apigenin can  inhibit COX‐2 strongly by 




Figure  1‐7.  The  proposed  action  mechanism  of  flavonoids.  Flavonoid  (F),  nonsteroidal  anti‐












 (Adiantaceae);  Asplenium  (Aspleniaceae);  Acacia  (Fabaceae);  Mentha  (Lamiaceae);  Baeckea, 
Melaleuca  and  Syncarpia  (Myrtaceae);  Pittosporum  (Pittosporaceae);  Hakea  and  Telopea 
(Proteaceae);  Pimelea,  (Thymelaeaceae)]  were  screened  which  were  important  to  the  same 
Aboriginal  clan  for  their  anti‐inflammatory  or  related  activity.  After  screening,  two  plants  from 
Eucalyptus  Spp.  (E.  viminalis  and  E.  bosistoana;  Chaper  3)  and  four  other  plants  [Melaleuca 
linarifolia, Syncarpia glomulifera subsp. glomulifera, Baeckea ramosissima subsp. ramosissima and B. 






Sequential  solvent  extraction  is  a  convenient  and  commonly used  procedure  to  isolate  unknown 
compounds.  A  series  of  solvents  from  non‐polar  to more  polar  were  used  to  comprehensively 
extract the plant material. The extractant is usually concentrated under vacuum, once the extraction 
is  done  ensuring  the  volatile  constituents  are  not  lost  [84].  Sequential  solvent  extraction  also 
facilitates the separation of  lipophilic  from hydrophilic compounds  [85]. Hexane, dichloromethane, 
ethyl acetate, ethanol, methanol and water were used as sequential solvents and soxhlet extraction 
has been carried out in this dissertation.  Each of the extracts was then screened for bioactivity and 




Bioassay‐guided  fractionation  is  a modern  strategy  to  isolate  and  identify  active  lead  compounds 




were  then  evaluated  by  the  bioassays  and  fractions  with  the  desired  biological  activity  in  the 





A number of  techniques  are  available  to  isolate  and purify bioactive natural products  from plant 
extracts.  Solvent  partitioning  or  liquid‐liquid  partitioning  is  a  fast  and  simple  technique,  which 
separates  fractions  based  on  their  relative  solubility  in  different  solvents.  Chromatographic 
techniques  include  vacuum  liquid  chromatography  (VLC),  flash  chromatography  (FC),  column 
chromatography  (CC),  size  exclusion  chromatography  (SEC),  solid‐phase  extraction  (SPE),  droplet 
counter‐current  chromatography  (DCC)  or  preparative  high  performance  chromatography  (prep‐
HPLC)  [89].  The most widely used  isolation  techniques  are probably  Liquid Chromatography  (LC), 
including  open  column  chromatography  and  High  Performance  Liquid  Chromatography  (HPLC). 
Other  separation  techniques  include  gas  chromatography  (GC),  capillary  electrophoresis  (CE)  and 








Based  on  the  principle  of  chromophore  formation,  the  Griess  method  is  diazotization  of 
sulphanilamide  by  nitrite  in  acidic  conditions  followed  by  coupling with  bicyclic  amines,  i.e. N‐1‐




























cytokines. This method  is highly quantitative and generally  reproducible.  In  the  traditional double 
antibody sandwich ELISA  (Figure 1‐9), an antibody attached to the bottom of a well provides both 
antigen  capture  and  immune  specificity,  while  another  antibody  linked  to  an  enzyme  provides 
detection and an amplification factor which enables accurate and sensitive detection of the cytokine 
(antigen) of  interest  [92]. To quantify  the amount of TNF‐α, avidin‐horseradish peroxidase  (avidin‐
HRP) conjugate  is added to allow colour formation  in the presence of tetramethylbenzidine (TMB). 
Subsequently,  brilliant  blue  colour  can  be  detected with  a  spectrophotometer  at  655  nm.  Then 

















Alamar blue (resazurin)  is a dye reagent which  is blue  in colour and virtually nonfluorescent. Upon 
entering cells, resazurin is reduced to resorufin, which produces very bright red fluorescence. Viable 
cells  continuously  convert  resazurin  to  resorufin  (Figure  1‐10),  thereby  generating  a  quantitative 












The  structure  elucidation  of  bioactive  natural  products  traditionally  depends  on  analysing 
spectroscopic  data  including mass  spectroscopic  data,  IR, UV  and NMR  spectroscopy  [96,97].  As 
stated by Halabalaki et al., NMR  is an  indispensable analytical method  in all  structure elucidation 
protocols [98]. Determination of stereochemistry usually depends on interpretation of NMR spectra, 
including  2D  spectra,  optical  rotation  values  and  circular  dicroism  spectroscopy. Dereplication  of 
known  compounds  can  be  obtained  by  interpreting mass  spectrometry,  1D  NMR  spectroscopic 
analysis and database searches. The most used databases  in this dissertation are the Dictionary of 
Natural Products (DNP) and SciFinder. Structure elucidation of new compounds needs more in‐depth 
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Corrections for the typographical errors in Chapter 2 
Chapter 2 has few typographical errors for which the following corrections are provided. 
On page 39 (page 3 of the paper), right column, 2nd paragraph (2.5. Activation of RAW 264.7 
Macrophages); 
Incorrect: is 
Correct: was  
On page 40 (page 5 of the paper), left column, 4th paragraph (2.9. Data presentation and Analysis), 
line 6; 
Incorrect: In addition, linear relationships and significance tests of these data sets were also 
conducted. 
Correct: Added mistakenly, should be omitted.  
Incorrect: growth curve analysis in dose-dependent experiments 
Correct: sigmoidal dose-response experiments 
On page 40 (page 5 of the paper), right column, 3rd paragraph (3. Results and Discussion), line 5 and 
2nd last line; 
Incorrect: are 
Correct: were 
On page 41 (page 6 of the paper), right column, paragraph 2 (4. Conclusion), last sentence; 
Incorrect: Purification and structure identification of the most these extracts are currently 
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Chronic inflammation contributes to multiple ageing-related musculoskeletal and neurodegenerative diseases, cardiovascular
diseases, asthma, rheumatoid arthritis, and inflammatory bowel disease. More recently, chronic neuroinflammation has
been attributed to Parkinson’s and Alzheimer’s disease and autism-spectrum and obsessive-compulsive disorders. To date,
pharmacotherapy of inflammatory conditions is based mainly on nonsteroidal anti-inflammatory drugs which in contrast to
cytokine-suppressive anti-inflammatory drugs do not influence the production of cytokines such as tumour necrosis factor-
𝛼 or nitric oxide. However, their prolonged use can cause gastrointestinal toxicity and promote adverse events such as high
blood pressure, congestive heart failure, and thrombosis. Hence, there is a critical need to develop novel and safer nonsteroidal
anti-inflammatory drugs possessing alternate mechanism of action. In this study, plants used by the Dharawal Aboriginal
people in Australia for the treatment of inflammatory conditions, for example, asthma, arthritis, rheumatism, fever, oedema, eye
inflammation, and inflammation of bladder and related inflammatory diseases, were evaluated for their anti-inflammatory activity
in vitro. Ethanolic extracts from 17 Eucalyptus spp. (Myrtaceae) were assessed for their capacity to inhibit nitric oxide and tumor
necrosis factor-𝛼 production in RAW 264.7 macrophages. Eucalyptus benthamii showed the most potent nitric oxide inhibitory
effect (IC
50
5.57 ± 1.4 𝜇g/mL), whilst E. bosistoana, E. botryoides, E. saligna, E. smithii, E. umbra, and E. viminalis exhibited nitric
oxide inhibition values between 7.58 and 19.77 𝜇g/mL.
1. Introduction
Inflammation is an important biological process and is
essential to maintain the body’s homeostasis, to fight against
pathogens effectively, and to repair the damaged tissue [1].
Howeverwhenuncontrolled and chronic, inflammation gives
rise to a number of (often age related) diseases including
asthma, rheumatoid arthritis, inflammatory bowel disease,
Crohn’s disease, and tendonitis. Furthermore, a chronic
inflammatory response with accompanying oxidative stress
is a significant force driving the progression of peripheral
diseases like atherosclerosis, diabetes, and metabolic syn-
drome, as well as neurodegenerative diseases such asmultiple
sclerosis, Parkinson’s disease, and Alzheimer’s disease [2–5].
While some chronic/remitting neurological diseases,
such as multiple sclerosis, have long been recognized as
inflammatory, the term “neuroinflammation” is now applied
to chronic activation of microglia and astroglia that do not
reproduce the classic characteristics of inflammation in the
periphery but may cause neurodegeneration [6–8]. Some
examples of diseases characterized by neuroinflammation
are Alzheimer’s disease (AD) and Parkinson’s disease and
even autism-spectrum and obsessive-compulsive disorders
[9–12]. Microglial and astroglial activation, accompanied by
increased levels of proinflammatory mediators such as TNF-
𝛼, IL-1𝛽 and IL-6, prostaglandins, and reactive oxygen and
nitrogen species, as well as reactive carbonyl species and
advanced glycation end products, is observed in the AD
brain at all stages of the disease [13–18]. Genetic and phar-
macoepidemiological studies also point to the importance of
inflammation in AD. For example, three immune-relevant
genes were shown to be associated with an increased risk of
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AD; these are CLU (clusterin), CR1 (complement receptor 1),
and TREM2 (triggering receptor expressed on myeloid cells
2) [19].
Consequently, targeting chronic neuroinflammation, for
example, with plant-derived anti-inflammatory compounds,
has been suggested as a promising disease-modifying treat-
ment for many neurodegenerative diseases including AD
[12, 20–27].
At present, both steroidal and nonsteroidal anti-in-
flammatory drugs (NSAIDs) are used to treat inflammation.
NSAIDs in particular can cause severe side effects, most
importantly gastric ulcers. NSAIDs are specifically designed
as inhibitors of cyclooxygenase (COX) enzymes and, in
contrast to CSAIDs, do not influence the production of
proinflammatory cytokines such as TNF-𝛼 or free radicals
such as nitric oxide [28]. CSAIDs specifically target p38
MAPK and NF-𝜅B signalling pathways to inhibit cytokine-
mediated events with demonstrated efficacy in a range of
animal models [29, 30].
Activated inflammatory cells produce a variety of
chemokines and cytokines, reactive oxygen species (ROS),
reactive nitrogen species (RNS), free radicals, and prostagl-
andins [31–33] and cease to produce neuroprotective factors
such as glutathione [6, 7].
Excessive production of inflammatory cytokines and
reactive radical species can damage cellular biomolecules like
proteins, lipids, and carbohydrates as well as nucleic acids,
leading to cellular and tissue damage, which further perpet-
uates the inflammatory cascade. Therefore, pharmacological
compounds with the ability to attenuate the production of
these inflammatory molecules may have potential for the
treatment of many inflammatory diseases including AD [21,
22, 28, 34, 35].
The use of natural substances, especially those derived
from plants, in order to prevent, manage, or cure diseases
is a centuries-old practice which has led to the discovery of
many modern pharmaceuticals. In recent years, the search
for novel anti-inflammatory drugs from a wide range of
medicinal plant resources has been intensified, and a variety
of plant secondarymetabolites including apigenin, curcumin,
cinnamaldehyde, and resveratrol have already been found to
suppress inflammatory responses [21, 22, 28].
For example, turmeric (Curcuma longa) and its main
ingredient curcumin, which has long been used for treat-
ment of rheumatic disorders, exerts both anti-inflammatory
and antiatherosclerotic effects [23, 36]. Ginger extract (Zin-
giber zerumbet) and its main active compound, 3-O-methyl
kaempferol, significantly attenuated carrageenan-induced
mouse paw oedema in an in vivo model and were also





), as well as iNOS expression in a
cell culture model. Aqueous and hydroalcoholic as well as
ethanolic extracts from another ginger species (Zingiber offic-
inale) demonstrated significant anti-inflammatory activity
and its active constituent [6] gingerol again showed anti-
inflammatory activity by inhibiting the production ofNOand
PGE
2
[37] and was also successful in inhibiting carrageenan-
induced rat paw oedema [38].
Triterpenoid saponins, from the Australian desert tree
Acacia victoriae, have shown anti-inflammatory effects via
inhibiting activation of NF-𝜅B, by preventing its nuclear
localization and inhibiting its ability to bind to DNA [39].
Another Australian indigenous plant Tinospora smilacina
is claimed to possess long chain unsaturated fatty acids
which possess anti-inflammatory properties [40]. The fruits
of the Australian native Kakadu plum (Terminalia ferdi-
nandiana), Illawarra plum (Podocarpus elatus), and Native
currant (Acrotriche depressa) also exhibited significant anti-
inflammatory activity [41].
There is large scope to investigate Australian native plants
for their bioactivity and chemical constituents [42]. Tradi-
tionalmedicine is still practised by themany tribal Aboriginal
people, particularly in Central and Northern Australia and
this ethnomedicinal knowledge is recorded in some cases
[43]. The “Dharawal Pharmacopeia” written by botanist and
Aboriginal Elder Frances Bodkin (known as Aunty Fran) is a
compilation of the Aboriginal medicinal and ceremonial uses
(and corresponding taxonomic identification) of thousands
of nativeAustralian plants. Of interest to our research, a num-
ber of plant species described in the Dharawal pharmacopeia
have been claimed to possess anti-inflammatory activities
(Table 1) [44, 45]. Plants from Eucalyptus species have special
importance for the Dharawal indigenous people and are
used for their anti-inflammatory activity along with other
medicinal uses as well as for shelter and weapons. As stated in
theDharawal pharmacopeia, Eucalypts aremostly distributed
in Blue Mountains, Southern Highlands, Woronora Plateau,
and coastal area of New South Wales, Australia.
The aim of our research is to evaluate the anti-inflam-
matory activity of Australian native plants with ethnophar-
macological importance and subsequently characterise the
bioactive components. In this manuscript, dried extracts
from 17 Eucalyptus spp. were evaluated for anti-inflammatory
activity via the suppression of NO and TNF-𝛼 production
induced by lipopolysaccharide (LPS) and interferon gamma
(IFN-𝛾) in RAW264.7 cells. Cytotoxicity of the crude extracts
was also examined using an Alamar blue cell viability assay.
2. Materials and Methods
2.1. Plant Material. Plants known to be used by the Dharawal
people (also known as Tharawal) to treat inflammation and
related illnesses were selected under the guidance of botanist
and Aboriginal Elder Auntie Fran (Frances Bodkin) and
the Dharawal pharmacopeia. Leaf material of 17 Eucalyptus
spp. was collected in the month of August, 2015 from
the “Australian Botanic Gardens” at Mount Annan, NSW,
Australia (Table 1).
2.2. Chemicals and Reagents. Ethanol was purchased from
Chem-Supply (Gillman, SA, Australia); bovine serum albu-
min, lipopolysaccharide (E. coli serotype-0127:B8), EDTA,
N-(1-napthyl) ethylenediamine dihydrochloride, benzylpen-
icillin G sodium salt, resazurin sodium salt (10%), strepto-
mycin, sulphanilamide, 3,3󸀠,5,5󸀠-tetramethylbenzidine (TMB),
trypan blue, and Dulbecco’s Modified Eagle’s Medium
(DMEM) were purchased from Sigma-Aldrich (Castle Hill,
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Table 1: Plants collected for the study of anti-inflammatory activity.
Number Plant APNI name Family Voucher number
(1) Eucalyptus acmenoides Eucalyptus acmenoides Schauer Myrtaceae 961604
(2) Eucalyptus benthamii Eucalyptus benthamiiMaiden & Cambage Myrtaceae 832452
(3) Eucalyptus bosistoana Eucalyptus bosistoana F. Muell. Myrtaceae 20070782
(4) Eucalyptus botryoides Eucalyptus botryoides Sm. Myrtaceae 861776
(5) Eucalyptus eximia Eucalyptus eximia Schauer Myrtaceae 841857
(6) Eucalyptus globoidea Eucalyptus globoidea Blakely Myrtaceae 873240
(7) Eucalyptus gummifera Eucalyptus gummifera (Gaertn.) Hochr. Myrtaceae 892074
(8) Eucalyptus maculata Eucalyptus maculataHook. Myrtaceae 20070782
(9) Eucalyptus notabilis Eucalyptus notabilisMaiden Myrtaceae 20020217
(10) Eucalyptus paniculata Eucalyptus paniculata Sm. Myrtaceae 840775
(11) Eucalyptus pilularis Eucalyptus pilularis Sm. Myrtaceae 861796
(12) Eucalyptus punctata Eucalyptus punctata DC. Myrtaceae 861820
(13) Eucalyptus resinifera Eucalyptus resinifera Sm. Myrtaceae 911862
(14) Eucalyptus saligna Eucalyptus saligna Sm. Myrtaceae 872719
(15) Eucalyptus smithii Eucalyptus smithii R. T. Baker Myrtaceae 361827
(16) Eucalyptus umbra Eucalyptus umbra R. T. Baker Myrtaceae 900782
(17) Eucalyptus viminalis Eucalyptus viminalis Labill. Myrtaceae 861830
NSW, Australia). GIBCO, fetal bovine serum (FBS), and
glutaminewere purchased fromLife Technologies (Mulgrave,
VIC, Australia). Murine interferon-𝛾 (IFN-𝛾) and TNF-𝛼
ELISA kits were purchased from PeproTech Asia (Rehovot,





) were from AJAX Chemicals (Auburn, NSW,
Australia). Tween-20 was fromAmresco (Solon, Ohio, USA).



















) was BDH brand supplied by
Merck Pty. Ltd. (Kilsyth, VIC, Australia).
2.3. Extraction of Plants Leaves for Biological Assays andHPLC
and MS Analysis. Approximately 40 g of fresh leaf material
from each plant was extracted using absolute ethanol. The
leaves were first cut into small pieces with scissors and
then ground to a coarse powder using a hand blender. The
coarse powder was filled into the thimbles of an accelerated
solvent extraction system (Buchi B-811, Switzerland) and then
extracted under standard soxhlet mode (for 2 × 15 minutes
cycles). The volume of the extracts was reduced to ca. 2–4
mL using a rotary evaporator and then evaporated to dryness
with nitrogen gas for biological assays. Percentage yields
(g/g% fresh weight) are recorded in Table 2.
2.4.Maintenance and Preparation of RAW264.7Macrophages.
RAW 264.7 macrophages were grown in 175 cm2 culture
flasks on DMEM (Dulbecco’s Modified Eagle’s Medium)
containing 5% FBS (fetal bovine serum) that was supple-
mented with antibiotics (1%) and glutamine (1%). The cell
line was maintained in 5% CO
2
at 37∘C, with media being
replaced every 3-4 days. Once cells had grown to confluence
in the culture flask, they were removed using a rubber
policeman cell scraper, as opposed to using trypsin, which
can remove membrane-bound receptors such as RAGE. The
cell suspension was concentrated by centrifugation for 3 min
at 900 rpm and resuspended in a small volume of fresh
DMEM (with 1% antibiotics and 5% FBS). Cell densities
were estimated using a Neubauer counting chamber. Cell
concentration was adjusted with DMEM (with 1% antibiotics
and 5%FBS) to obtain 60000 cells/100𝜇L cell suspension.The
100 𝜇L cell suspensionwas then dispensed into the innerwells
of 96-well plates. Plates were incubated at 37∘C and 5% CO
2
for 18 h before the activation experiments were carried out.
2.5. Activation of RAW 264.7 Macrophages. From each well,
the media were removed and replaced with fresh DMEM
containing 0.1% FBS. For assays with extracts, a 90 𝜇L volume
of the dilutions in DMEM (with 0.1% FBS) was added an
hour prior to addition of the activator. Due to the often
inconsistent nature of LPS at activating cells, a combination of
LPS (10 𝜇g/mL) and IFN-𝛾 (10U/mL), both in DMEM (with
0.1% FBS), was used for activation. A maximum dose of the
extracts used is 900 𝜇g/mL and diluted serially by 50% up to
a minimum of 10 doses (900, 450, 225, 112.5, 56.25, 28.125,
14.062, 7.031, 3.515, 1.7578, and 0.8789𝜇g/mL in the wells,
resp.). After activation, the cells were incubated for 24 h at
37∘C and 5% CO
2
and then NO and TNF-𝛼 inhibition and
cell viability were determined. Cells with media alone were
used as negative control and activated cells used as positive
control.
2.6. Determination of Nitric Oxide Production by Griess Assay.
Nitric oxide was determined by Griess reagent quantification
of nitrite, one of its stable reaction products. Griess reagent
was freshlymade up of equal volumes of 1% sulfanilamide and
0.1% naphthylethylene-diamine in 5% HCl. In the presence
of nitrite this reagent forms a violet colour. From each
well, 50 𝜇L of supernatant was transferred to a fresh 96-
well plate and mixed with 50 𝜇L of Griess reagent, and the
colour produced was measured at 540 nm in a microplate
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reader (Bio-Rad, Australia).The remaining supernatant from
each well was used for a TNF-𝛼 assay using commercial
sandwich ELISA development kits (catalog number: 900-
K54; PeproTech, USA).
2.7. Determination of Cell Viability by Alamar Blue Assay. The
Alamar Blue assay is a colorimetric assay involving the cellu-
lar reduction of resazurin to resorufin. Alamar Blue solution
[100 𝜇L of 10% Alamar Blue (resazurin) in DMEM medium]
was added to each well and incubated at 37∘C for 1-2 h.
After incubation, fluorescence was measured (excitation at
530 nm and emission at 590 nm) using a POLARstar Omega
microplate reader (BMG Labtech, Mornington, Australia)
and expressed as a percentage of that in control wells after
background fluorescence was subtracted.
2.8. TNF-𝛼 Determination by ELISA. The supernatants ob-
tained from each well (remaining supernatant after 24 hours
of activation) were diluted 30 times using diluent (0.1%









, and 154mM NaCl;
pH 7.4]) and were used for determination of TNF-𝛼 using
a commercial sandwich ELISA (catalog number: 900-K54;
Peprotech, USA) according to the manufacturer’s protocol.
Capture antibody was used at a concentration of 1.25 𝜇g/mL
inPBS. Tomake a standard curveTNF-𝛼 (10 ng/mL standard)
was diluted serially by 50% up to a minimum of 10 doses
(10, 5, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.039, 0.019, and
0.0097 ng/mL in the wells, resp.) and was used as the internal
standard. TNF-𝛼 was detected with a biotinylated second
antibody and an avidin peroxidase conjugate with TMB as
detection reagent. After ∼30min, the reaction was stopped
using 0.5M sulfuric acid, and the absorbance was measured
at 450 nm of measurement filter with a 655 nm of reference
filter. The absorbance data was expressed as a percentage of
that in control wells after conversion of the concentrations
by using a standard curve constructed with defined con-
centrations of TNF-𝛼. Curve fitting of this standard curve
and extrapolation of experimental data were performed using
nonlinear regression analysis.
2.9. Data Presentation and Analysis. As the experiments were
done in triplicates, the results were expressed as the mean ±
SEM. In addition, linear relationships and significance tests of
these data sets were also conducted. GraphPad Prism version
6.01 (GraphPad Software Incorporated, USA) was used for
growth curve analysis in dose-dependent experiments and to
determine the IC
50




3. Results and Discussion
In this study, leaves from 17 different Eucalyptus spp. were
collected in the month of August, 2015. Approximately 40 g
of leaves from each of Eucalyptus acmenoides, E. benthamii,
E. bosistoana, E. botryoides, E. eximia, E. globoidea, E. gum-
mifera, E. maculate, E. notabilis, E. paniculata, E. pilularis, E.
punctate, E. resinifera, E. saligna, E. smithii, E. umbra, and E.
viminalis were extracted using absolute ethanol (Table 2).
The RAW 264.7 murine macrophages release NO and
TNF-𝛼when exposed to bacterial LPS and IFN-𝛾 and on this
principle, has become an established experimental model to
evaluate in vitro anti-inflammatory activity of extracts [28].
For the purpose of interpretation, the IC
50
values of NO
inhibition are divided into three groups: extracts with IC
50
<
20𝜇g/mL are considered as highly potent extracts; a value
between 21 and 80 𝜇g/mL is considered as moderately potent,
and an IC
50
< 80 𝜇g/mL is considered as an extract with low
potency.
The highest concentration of ethanolic crude extract
tested in the anti-inflammatory assay was 900 𝜇g/mL with
0.5-fold serial dilutions. Eucalyptus benthamii, E. bosistoana,
E. botryoides, E. saligna, E. smithii, E. umbra, and E. viminalis
leaf extracts showed the highest activity for NO inhibition
with IC
50
values of 5.57, 7.58, 16.65, 19.77, 17.62, 17.69, and
8.0 𝜇g/mL, respectively (Table 3, Suppl. Figure 1).The extracts
from Eucalyptus acmenoides, E. eximia, E. notabilis, and
E. pilularis showed moderate inhibition of NO with IC
50
values of 56.93, 34.14, 53.84, and 76.17 𝜇g/mL, respectively.
Six other species, E. globoidea, E. gummifera, E. maculata,
E. paniculata, E. punctata, and E. resinifera, presented low
inhibition of NO with IC
50
values of 82.9, 108.17, 99.94, 130.7,
120.4, and 81.21𝜇g/mL, respectively (Suppl. Figure 1).
The plant extracts also showed promising TNF-𝛼
inhibitory activity (Table 3) with IC
50
values of 2.06, 8.53,
19.02, 3.41, 2.41, 10.2, and 16.68 𝜇g/mL for E. benthamii, E.
bosistoana, E. botryoides, E. saligna, E. smithii, E. umbra,
and E. viminalis, respectively, which are the same plants
in our highly potent NO inhibitor group. On the other
hand, the moderately potent extracts from E. acmenoides,
E. eximia, E. notabilis, and E pilularis showed TNF-𝛼 IC
50
values of 16.53, 4.82, 27.48, and 21.09 𝜇g/mL, respectively
(Suppl. Figure 1), whereas extracts from E. globoidea, E.
gummifera, E. maculata, E. paniculata, E. punctata, and E.
resinifera exhibited comparatively lower inhibition of TNF-𝛼
production with IC
50
values of 50.73, 82.73, 136.34, 334.86,
115.73, and 62.11𝜇g/mL, respectively, which are the plants in
our low potency group (Suppl. Figure 1).
The use of Alamar Blue (resazurin) to measure cytotoxic-
ity is an established technique [46].The results of cytotoxicity
(LD
50
) of our leaf extracts are shown in Table 3. The plants of
our highly potent group were also relatively toxic with LC
50
values of 22.34, 37.17, 108.40, 101.01, 38.96, 236.5, and 31.92 for
E. benthamii, E. bosistoana, E. botryoides, E. saligna, E. smithii,
E. umbra, and E. viminalis, respectively, whereas, plants of the
lower potency group showed lower toxicity with higher LD
50
values of 464.74, 313.45, 540.46, 268.59, 522.84, and 268.59
for E. globoidea, E. gummifera, E. maculata, E. paniculata, E.
punctata, and E. resinifera, respectively. Plants with moderate
potency showed a wide range of cytotoxicity with LD
50
values of 296.22, 64.14, 332.44, and 374.74 for E. acmenoides,
E. eximia, E. notabilis, and E. pilularis, respectively (Suppl.
Figure 1).
In future experiments, we will purify the most potent
extracts to identify the most active compounds. One major
candidate for carrying the anti-inflammatory activity could
be 1,8- cineole, the major monoterpene of eucalyptus oil,
as it can represent between 60 and 80% of the volatile oils
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Table 3: Anti-inflammatory activity and toxicity of extracts determined in RAW 264.7 macrophages.
Plant species Inhibition of NO production(IC
50
in 𝜇g/mL)








Eucalyptus acmenoides 56.93 ± 11.8 16.53 ± 5.9 296.22 ± 189.3
Eucalyptus benthamii 5.57 ± 1.4 2.06 ± 0.7 22.34 ± 9.3
Eucalyptus bosistoana 7.58 ± 1.2 8.53 ± 3.4 37.17 ± 15.6
Eucalyptus botryoides 16.65 ± 2.2 19.02 ± 5.4 108.40 ± 44.9
Eucalyptus eximia 34.14 ± 7.1 4.82 ± 1.6 64.14 ± 23.6
Eucalyptus globoidea 82.9 ± 12.5 50.73 ± 24.0 464.74 ± 199.7
Eucalyptus gummifera 108.17 ± 10.5 82.73 ± 52.3 313.45 ± 125.9
Eucalyptus maculata 99.94 ± 12.1 136.34 ± 78.8 110.22 ± 41.1
Eucalyptus notabilis 53.84 ± 7.7 27.48 ± 14.9 332.44 ± 107.5
Eucalyptus paniculata 130.7 ± 11.6 334.86 ± 192.7 540.46 ± 172.5
Eucalyptus pilularis 76.17 ± 10.3 21.09 ± 9.7 374.74 ± 190.7
Eucalyptus punctata 120.4 ± 15.9 115.73 ± 58.4 522.84 ± 221.4
Eucalyptus resinifera 81.21 ± 13.4 62.11 ± 36.0 268.59 ± 131.6
Eucalyptus saligna 19.77 ± 2.3 3.41 ± 1.3 101.01 ± 36.8
Eucalyptus smithii 17.62 ± 3.5 2.41 ± 1.1 38.96 ± 14.1
Eucalyptus umbra 17.69 ± 2.3 10.2 ± 4.5 236.5 ± 144.3
Eucalyptus viminalis 8.0 ± 1.2 16.68 ± 9.9 31.92 ± 11.9
Note. Results represent the mean ± SEM of 3 experiments in triplicate for NO production and cytotoxicity whereas for TNF-𝛼 production it is 1 experiment in
triplicate.
derived from eucalyptus leaves depending on the species.
Therapeutic concentrations of 1,8-cineol (1.5𝜇g/mL = 10−5M)
inhibited significantly cytokine production in lymphocytes
and monocytes [47, 48]. It has to be noted that 1,8-cineol has
already gained market acceptance for its anti-inflammatory
properties in mouthwashes and cough suppressants or anti-
asthmatic medications [48, 49].
The plants studied here were chosen on the basis of
their traditional use to treat inflammatory conditions by
the Dharawal people of the Campbelltown region (South-
west Sydney Australia). All of the plants showed anti-
inflammatory activity and demonstrated inhibitory effect on
downregulation of NO and TNF-𝛼 production with varying
potencies, which supports their use in traditional Aboriginal
medicine. The content of the anti-inflammatory compounds
in the plants, according to traditional knowledge, is also
dependent on the plant’s environment. In Dharawal country,
what is most important when seeking particular medicines
from plants is where the plant is growing, that is, not
so much the soils, but the other plants that are growing
around the particular plant required. For instance, with the
Eucalypts, close proximity of an Ironbark (Muggago) and a
Ribbon bark (Kai’yeroo) is needed for the anti-inflammatory
medicine from the Burringoa (Eucalyptus tereticornis) to be
most effective. As another example, the Ironbark itself does
not need other Eucalypts close by, but it does need the
Einadia (one of the saltbushes) to be growing at its base.
In addition, if it had been struck by lightning (and this
can be confirmed by a line of interrupted bark running
from the top of the tree almost to its base), then the anti-
inflammatory medicine would be most effective, when using
the leaves of the Eucalypts as medicine, the leaves of the
trees younger than 7 years were placed on a low fire and the
smoke inhaled. However, when the tree is bearing the mature
leaves, the leaves were collected and boiled then allowed to
cool before being rubbed on the affected part of the body,
depending on the species. For the present screening study,
the plant material was provided by the Botanical Gardens
from random trees in the garden, but for future studies,
we will investigate if collection practice based on Dharawal
knowledge will improve the inherent activity and/or yield of
the anti-inflammatory compounds.
4. Conclusions
The present study suggests that most of the Eucalyptus
spp. potentially possess interesting anti-inflammatory com-
pounds with low toxicity and the in vitro activity appears
to support the traditional use. Eucalyptus benthamii, E.
bosistoana, E. botryoides, E. saligna, E. smithii, E. umbra, and
E. viminalis leaf extracts exhibited strong anti-inflammatory
activity by inhibiting NO and TNF-𝛼 production in LPS
and INF-𝛾 stimulated RAW 264.7 macrophages. Purification
and structure identification of the most these extracts are
currently underway.
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Ethical engagement of Aunty Bodkin with Western Sydney University (WSU) 
 
In 2012, Frances Bodkin (Auntie Fran - a D’harawal elder), through the D’harawal Traditional 
Descendents’ and Knowledgeholders’ Circle (DTDKC) donated the D’harawal Pharmacopeia to Western 
Sydney University (WSU), Campbelltown campus, specifically for utilisation in teaching and learning 
within the Mangamai'bangawarra: Indigenous Science course. This remains a particularly unique 
circumstance and rarely observed, where cultural traditional knowledge is donated to an institution. A 
key determinant influencing the decision made by the DTDKC to donate the knowledge to WSU is it was 
considered the best way to protect the knowledge (in the present state of the law), by entrusting it to the 
one university situated on the land of their ancestors and knowledge. In doing so, it was requested that if 
any (economic) benefit is derived from the knowledge, that it be used to allow Aboriginal students born 
of D’harawal Lands to attend WSU to study science (for example, through scholarships). 
A letter provided to the university from the D’harawal Traditional Descendents’ and Knowledgeholders’ 
Circle outlines their endorsement of Auntie Fran ‘to advise and assist the group in their search for greater 
knowledge of Aboriginal medicines’, entrusting the knowledge to the university as the best means of 
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Preface to Chapter 3 
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A new 5,7-dihydroxychromone compound (1) was isolated from the leaf extract of Eucalyptus viminalis (Myrtaceae), along with two known compounds        
(2 and 3). Their structures were elucidated on the basis of mass and NMR spectroscopic data analysis. Compound 1 showed moderate anti-inflammatory 
activity by down-regulating nitric oxide in LPS (Lipopolysaccharide) and IFN-γ (Interferon gamma) treated RAW 264.7 macrophages and N-11 microglial 
cells with an IC50 value for nitric oxide downregulation of 44.0 ± 9.0 μg/mL and 43.4 ± 7.3 µg/mL respectively. Compound 1 was non-toxic to RAW 
macrophage and N-11 microglial cells ( >36 μg/mL). 
 




Native to Australia, the genus Eucalyptus (family Myrtaceae) 
represents more than 700 species and is distributed throughout the 
world. This genus is a fast growing tree and has long been used in 
folk medicine. Eucalypts are rich in variety of essential oils[1-6]. 
Modern pharmaceutical, food and cosmetic industries also use 
essential oils from Eucalyptus species [7-11]. 
 
Plants from Eucalyptus species have special importance for the 
D’harawal indigenous people of Australia and are used for their 
anti-inflammatory activity along with other medicinal uses as well 
as for shelter and weapons. Eucalyptus viminalis are mostly 
distributed in Blue Mountains, Southern Highlands, Woronora 
Plateau, and across the coastal area of New South Wales, Australia 
[12]. In a recent study sixty six compounds were identified in the oil 
of E. viminalis leaves, the major compounds being 1,8-cineole, α-
pinene, limonene and globulol by hydro-distillation and GC/MS 
[13]. The essential oil from E. viminalis has also been investigated 
for insecticidal and repellent activities [11, 14, 15]. Leaf extracts 
from E. viminalis have also known to demonstrate significant 
antimicrobial activities [8]. Euvimals derived from E. viminalis 
exhibited protonophoric activity which is considered to be the 
reason of their cytotoxic and antimicrobial activity [16]. 
 
In our previous study, E. viminalis leaf extract exhibited strong anti-
inflammatory activity by inhibiting NO (nitric oxide) and TNF-α 
(tumor necrosis factor-α) production in LPS (lipopolysaccharide)  
and INF- (interferon gamma)  stimulated RAW 264.7 macrophages 
indicating the potential of this plant to possess interesting anti-
inflammatory compounds with low toxicity [12].  
 
As part of our ongoing investigations into the discovery of new 
anti-inflammatory metabolites from plants we discovered the new 
chromone compound (1).  
 
Fresh leaves of E. viminalis were extracted sequentially using a 
range of different solvents (dichloromethane, ethyl acetate,   
ethanol, methanol and finally water). Immediately after the initial 
stages of sequential fractionation, each corresponding fraction    
was subjected to anti-inflammatory screening using the inhibition of  
 
Figure 1: Key 2D NMR correlations for 1. 
 
NO and TNF-α in LPS and IFN-γ treated RAW 264.7 macrophages 
following Griess test and TNF-α Elisa. Based on the bioactivity 
guided fractionation the most potent fraction was determined to be 
the ethyl acetate fraction which was subsequently further purified 
by semi-preparative reversed phase HPLC yielding compounds 1  
(tR = 18.6 min, 4.0 mg), 2 (tR = 15.7 min, 1.1 mg) and 3 (tR = 19.8 
min, 1.0 mg). 
 
HRESI(+)MS analysis of 1 revealed a pseudomolecular ion 
([M+H]+) indicative of a molecular formula C29H38O11 requiring 11 
double bond equivalents. The 1H NMR spectrum (Figure 1, Table 1) 
exhibited two singlet resonances for H-3 (H 6.07, C 109.1) and   
H-6 (H 6.14, C 98.8), the first of which showed HMBC 
correlations to several quaternary carbons C-2 (C 171.5), C-4 (C 
184.1), C-10 (C 105.4) and a methylene C-11 (c 44.3). The second 
showed HMBC correlations to additional quaternary carbons C-5 
(C 162.7), C-7 (C 163.8), C-8 (C 103.6) and to C-10. The 
following correlations suggested the likely existence of a 5,7-
dihydroxychromone system. COSY correlations from the methylene 
H2-11 extending through to the methine H-12 (H 2.36) and two sets 
of secondary methyl groups confirmed the attachment of the 
isobutyl unit at C-2. 
 
A comprehensive presence of oxymethines from H-1 to H-5 
terminating of at the hydroxy methylene H-6 prompted the 
presence of a sugar residue. Interestingly,  the  lack  of an  anomeric  
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Table 1: NMR (400 MHz, MeOH-d4) data for 1. 
 
Position δH, (m, J in Hz) δC* COSY HMBC 
2  171.5   
3 6.07, s 109.1  2, 4, 5, 10, 11 
4  184.1   
5  162.7   
6          6.14, s 98.8     5, 7, 8, 10 
7  163.8   
8  103.6   
9  158.8   
10  105.4   
11 2.63, 2.57, m 44.3 12 2, 3, 12, 13, 14 
12 2.36, m 28.1 11, 13, 14 11, 13, 14 
13 1.09, d (6.7) 22.8 12 11, 12, 14 
14 1.04, d (6.7) 22.9 12 11, 12, 13 
1 5.05, d (9.7) 72.5 2 2, 3, 7, 8, 9 
2 5.61, dd (10.0, 9.7) 73.7 1, 3 8, 1, 3, 7 
3 3.69, dd (10.0, 9.9) 77.8 2, 4 1, 2, 4 
4 3.46a, m 72.6 3, 5  
5 3.45a, m 82.7 4, 6  
6 3.92, 3.65, m 63.3 5’  
1  NO   
2 6.82, s 140.9 3  
3 2.24, 1.92, m 28.3 2, 4  
4 1.43, m 45.4 3, 5  
5 2.29, 1.96, m 26.3 4, 6  
6 1.91, m 24.3 5  
7  168.0   
8  72.7   
9 1.13b, s 26.7  4”, 8”, 9” 
10 1.13b, s 26.8  4”, 8”, 9” 
     




Figure 2: Chemical structures of 1 – 4. 
 
proton, but the presence of a downfield resonance for H-1 (H 5.05, 
C 72.5) coupled with its HMBC correlations to C-7, C-8 and C-9 
established the carbon linkage of the sugar residue to the chromone 
system (Figure 1). The final subunit was identified by a series of 
COSY and HMBC correlations to confirm the presence of oleuropeic 
acid (Figure 1. Table 1). A characteristic HMBC correlation from 
the oxymethine H-2 to the ester carbonyl C-7 confirmed the likely 
attachment of the oleuropeic ester carbonyl to C-2 of the sugar 
residue. Further confirmation of the oleuropeic acid moiety 
presence was determined by performing an acid hydrolysis on 1 to 
yield oleuropeic acid (4), confirmed by HRMS analysis (Figure 
S11) and the 8--glucopyranosyl residue (2). The furnished 
oleuropeic acid exhibited an optical rotation of []D
20  +68 (CHCl3) 
the closest comparison was with the reported literature value of 
oleuropeic acid methyl ester []D
20  +42.5 (CHCl3) [17], confirming 
the absolute stereochemistry at C-4 to be R. A relatively low yield 
of oleuropeic acid (4) after acid hydrolysis prevented any further 
NMR analysis. The relative stereochemistry of H-1 to H-2 was 
determined to be trans-1,2-diaxial to each other based on a large 
coupling of J1’,2’ (9.7 Hz), while also the large coupling of J2’,3’ 
(10.0 Hz) confirmed the trans-1,2-diaxial relationship between H-2 
and H-3. Also observed was a large coupling of  J3’,4’ (9.9 Hz), the 
coupling between H-4 and H-5 was not resolved, however based 
on the similarity of the glucosyl residue in the known metabolite 2 
[18], we propose a trans-diaxial orientation between these protons 
and the identity of the sugar as glucose. 
Table 2: NO and TNF-α down regulation and cytotoxicity of compounds (1 – 4 ) in 
LPS and IFN- induced RAW 264.7 macrophages. [Results represent mean ± SEM; 2 
experiments as quadruplicate (n=8)]. 
 
Compound Inhibition of 
NO production 
(IC50 in µg/mL) 
Inhibition of TNF-





1 44.0 ± 9.0 41.0 ± 23.8 > 36 
2 47.0 ± 7.8 38.3 ± 14.8 > 36 
3 37.6 ± 4.9 43.2 ± 18.4 > 36 
4 18.7 ± 0.5         21.5 ± 4.4 54.4 ± 21.4 
    
Positive control    
Diclofenac [19] 64.2 ± 12.7 > 99 > 99 
Ibuprophen [19]   237.9 ± 27.4 148.9 ± 53.8 > 309 
E-Cinnamaldehyde[20]  7.3 ± 1.2           8.3  ± 1.2 157.2 ± 29.8 
 
Compounds 1 – 4 were evaluated for their anti-inflammatory 
activity by determining the inhibition of NO and TNF- in both 
RAW 264.7 macrophage (Table 2) and N-11 microglial cells (Table 
3) [18, 21]. Although compounds (1 – 3) exhibited moderate anti-
inflammatory activities, it was oleuropeic acid [22] (4) that 
displayed the highest potency with an IC50 value from 10 – 20 
g/mL (Tables 2 and 3). Our current focus on Australian native 
plants, and a detailed anti-inflammatory chemical profiling has still 
to date lead to the discovery of new derivatives, and in the process 
has led us to evaluate for the first time a comprehensive anti-
inflammatory evaluation of a well known molecule, oleuropeic acid.   
 
Table 3: NO and TNF-α down regulation and cytoxicity of compounds (1 - 4) in LPS 
and IFN- induced N11 microglia. [Results represent mean ± SEM; 2 experiments as 
quadruplicate (n=8)]. 
 
Compound Inhibition of NO 
production (IC50 
in µg/mL) 
Inhibition of TNF-α 
production (IC50  in 
µg/mL) 
Cytotoxicity (LC50 in 
µg/mL) 
1 43.4 ± 7.3 20.4 ± 10.5 > 36 
2 34.1 ± 4.2 34.3 ± 18.1 >36 
3       21.8 ± 3.7         19.0 ± 7.1 > 36 




General: Acetonitrile, dichloromethane and methanol were 
supplied by Merck. Ethyl acetate from Fisher Chemical, ethanol 
from Chem-Supply and water used was Milli-Q water. Bovine 
serum albumin, lipopolysaccharide (E. coli serotype-0127:B8), 
EDTA, N-(1-napthyl) ethylenediamine dihydrochloride, 
benzylpenicillin G sodium salt, resazurin sodium salt (10%), 
streptomycin, sulphanilamide, 3,3ʹ,5,5ʹ-tetramethylbenzidine 
(TMB), trypan blue and Dulbecco’s Modified Eagle’s Medium 
(DMEM) were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia). GIBCO Foetal bovine serum (FBS) and glutamine were 
purchased from Life Technologies (Mulgrave, VIC, Australia). 
Murine interferon-γ (IFN-γ) and TNF-α ELISA kits were purchased 
from PeproTech Asia (Rehovot, Israel). Citric acid and 
monosodium dihydrogen carbonate (NaH2CO3) were from AJAX 
Chemicals (Auburn, NSW, Australia). Tween-20 was from 
Amresco (Solon, Ohio, USA). Methanol, monosodium phosphate 
(NaH2PO4), disodium phosphate (Na2HPO4), sodium chloride 
(NaCl) and sulfuric acid (H2SO4) were from Merck (Darmstadt, 
Germany). Sodium carbonate (Na2CO3) was BDH brand supplied 
by Merck Pty. Ltd. (Kilsyth, VIC, Australia). 
 
Semi-preparative HPLC was performed using an Agilent 1260 
Infinity Series (Santa Clara, CA, USA). NMR spectra were 
recorded on a Bruker Ascend 400 MHz spectrometer (Bruker 
Biospin GmbH, Bremen, Germany), in the solvents indicated and 
referenced to residual 1H signals in deuterated solvents. HRMS was 
carried out using a Waters Xevo Q-TOF mass spectrometer 
operating in the positive ESI mode. UV-Vis was measured using 
Shimadzu model UV-2550, and optical rotation measured on Polax-
D, ATAGO system at 22C. 
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Fresh leaves of E. viminalis (voucher no. 861830) were collected in 
July, 2016 from the ‘Australian Botanic Gardens’ at Mount Annan, 
NSW, Australia. The voucher specimen is deposited at the National 
Herbarium of NSW, Australia. 
 
Approximately 120 g of fresh leaf material from E. viminalis was 
first cut into small pieces and later ground to a coarse powder using 
a hand blender. The coarse powder was then extracted using an 
accelerated solvent extraction system (Buchi B-811, Switzerland) 
under standard soxhlet mode (for 2 × 15 min cycles) using five 
different solvents (dichloromethane, ethyl acetate, ethanol, 
methanol and water) sequentially from low to high polarity. The 
sequential extracts were then screened for their anti-inflammatory 
activity. The ethyl acetate extract was found to be most potent and 
so was subjected directly through reversed phase semi-prep HPLC 
(phenyl-hexyl column, 250 x 10 mm, Phenomenex) eluting with a 
gradient starting from 10% acetonitrile/water to a 100% acetonitrile 
(with a constant 0.01% formic acid modifier) over 30 min and held 
at 100% acetonitrile for 10 min to yield compounds 1 (tR = 18.6 
min, 4.0 mg), 2 (tR = 15.7 min, 1.1 mg) and 3 (tR = 19.8 min, 1.0 mg). 
 
Acid Hydrolysis of 1: A solution of 1 (2.0 mg) in 6 M HCl (2.0 mL) 
was heated for 3 hours at 70°C. After cooling, sodium hydroxide 
(2M) was added to the reaction mixture and the products purified 
using a Kinetex phenyl-hexyl column (250 x 4.6mm, 5µm) eluting 
with a gradient starting from 10% methanol/water to a 100% 
methanol (with a constant 0.01% formic acid as modifier) over 5 
min and held at 100% methanol for 5 min to yield compound 2 (1.0 
mg) and 4 (0.4 mg)  
 
Maintenance and Preparation of RAW 264.7 Macrophages and 
N11 Microglia: RAW 264.7 macrophages were grown in 175 cm2 
culture flasks on DMEM (Dulbecco’s modified eagle’s medium) 
containing 5% FBS (fetal bovine serum) that was supplemented 
with antibiotics (1%) and glutamine (1%). The cell line was 
maintained in 5% CO2 at 37°C, with media being replaced every 3-
4 days. Once cells had grown to confluence in the culture flask, they 
were removed using a rubber policeman cell scraper, as opposed to 
using trypsin, which can remove membrane-bound receptors such 
as RAGE. The cell suspension was concentrated by centrifugation 
for 3 min at 900 rpm and re-suspended in a small volume of fresh 
DMEM (with 1% antibiotics and 5% FBS). Cell densities were 
estimated using a Neubauer counting chamber. Cell concentration 
was adjusted with DMEM (with 1% antibiotic and 5% FBS) to 
obtain 60000 cells/100 µL cell suspension. The 100 μL cell 
suspension was then dispensed into the wells of 96-well plates and 
incubated at 37°C; 5% CO2 for 18 h before the activation 
experiments were carried out. 
 
Activation of RAW 264.7 Macrophages and N11 Microglia: From 
each well, the media was removed and replaced with fresh DMEM 
containing 0.1% FBS. For assays with extracts (conducted only 
with RAW 264.7 macrophages), a 90 μL volume of the dilutions in 
DMEM (with 0.1% FBS) was added an hour prior to addition of the 
activator. Due to the often inconsistent nature of LPS at activating 
cells, a combination of LPS (10 μg/mL) and IFN-γ (10 U/mL), both 
in DMEM (with 0.1% FBS), were used for activation. A maximum 
dose (36 µg/mL) of the compounds (1 - 3) was used, and diluted 
serially by 50% up to a minimum of 7 doses (36, 18, 9, 4.5, 2.25, 
1.12 and 0.56 µg/mL in the wells respectively), whereas a 
maximum dose of 90 µg/mL was used for compound 4, and diluted 
serially by 50% up to a minimum of 7 doses (90, 45, 22.5, 11.25, 
5.62, 2.81 and 1.41 µg/mL in the wells respectively). After 
activation, the cells were incubated for 24 h at 37°C and 5% CO2 
and then NO and TNF-α inhibition, and cell viability was 
determined. Cells with media alone were used as negative control 
and activated cells used as positive control. 
 
Determination of Nitric Oxide Production by Griess Assay: Nitric 
oxide was determined by quantification of nitrite one of its stable 
reaction products with the Griess reagent (GR). GR was freshly 
made up of equal volumes of 1% sulfanilamide and 0.1% 
naphthylethylene-diamine in 5% HCl. In the presence of nitrite this 
reagent forms a violet colour. From each well, 50 μL of supernatant 
was transferred to a fresh 96-well plate and mixed with 50 μL of 
GR, and the colour produced was measured at 540 nm in a 
microplate reader (Bio-Rad, Australia). The remaining supernatant 
from each well was used for a TNF-α assay using commercial 
sandwich ELISA development kits (catalog number: 900-K54; 
PeproTech, USA). 
 
Determination of Cell Viability of RAW 264.7 Macrophages and 
N11 Microglia by Alamar Blue Assay: The Alamar Blue assay is a 
colorimetric assay involving the cellular reduction of resazurin to 
resorufin. Alamar Blue solution [100 µL of 10% Alamar Blue 
(Resazurin) in DMEM medium] was added to each well and 
incubated at 37°C for 1-2 h. After incubation, fluorescence was 
measured (excitation at 544 nm and emission at 590 nm) using a 
POLARstar Omega microplate reader (BMG Labtech, Mornington, 
Australia) and expressed as a percentage of that in control wells 
after background fluorescence was subtracted. 
 
TNF-α Determination by ELISA: The supernatants obtained from 
each well (remaining supernatant after 24 h of activation) were 
diluted 30 times using diluent (0.1% w/v bovine serum albumin and 
0.05% v/v tween-20 in PBS [1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 
154 mM NaCl; pH7.4]) and were used for determination of TNF-α 
using a commercial sandwich ELISA (Catalog number: 900-K54; 
Peprotech, USA) according to the manufacturer’s protocol. Capture 
antibody was used at a concentration of 1.25 μg/mL in PBS. To 
make a standard curve TNF-α (10 ng/ml standard) was diluted 
serially by 50% up to a minimum of 10 doses (10, 5, 2.5, 1.25, 
0.625, 0.312, 0.156, 0.078, 0.039, 0.019 and 0.0097 ng/mL in the 
wells respectively) and was used as the internal standard. TNF-α 
was detected with a biotinylated second antibody and an avidin 
peroxidase conjugate with TMB as detection reagent. After ~30 
min, the reaction was stopped using 0.5 M sulfuric acid, and the 
absorbance was measured at 450 nm of measurement filter. The 
absorbance data was expressed as a percentage of that in control 
wells after conversion of the concentrations by using a standard 
curve constructed with defined concentrations of TNF-α. Curve 
fitting of this standard curve and extrapolation of experimental data 
were performed using non-linear regression analysis.  
 
Data Presentation and Analysis: Two experiments as 
quadruplicates (n=8) were combined to determine the IC50 (for NO 
and TNF-α inhibition) and LC50 (for cell viability) values using the 
four parameter sigmoidal dose-response function in GraphPad 




[α]D: + 5.5 (c 0.01, MeOH). 
UV/Vis λmax (MeOH) nm (log ε): 228 (4.19), 249 (4.01), 295 
(4.08)  
1H NMR (400 MHz, DMSO-d6): Table 1 
13C NMR (100 MHz, DMSO-d6): Table 1 
HRMS-TOF: m/z [M + H+] calcd for C29H39O11: 563.2492; found: 
563.2498 
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4-Coumaroyl quinic acid Isolated from 


















Eucalyptus  bosistoana  belongs  to  the  family  Myrtaceae.  As  described  in  the  D’harawal 
pharmacopoeia (unpublished), the plant is commonly known as coastal grey box and is an evergreen 
tree that grows to a height of 50 m. 
The  essential  oil  samples  of  Eucalyptus  bosistoana  from  Algerian  Sahara  have  been  previously 
investigated and  the main constituents  shown  to be p‐cymene,  cryptone, 1,8‐cineole,  spathulenol 
and α‐pinene [1].  
The plant has a number of medicinal uses according to the D’harawal pharmacopoeia    including;  i) 
the nectar was collected by washing the flowers in water until it had become sweet to taste, it was 
then  taken  to  treat  colds  and  breathing  difficulties  in  the  very  young  and  very  old,  ii)  the  bark 
exudate was used to relieve the pain of toothache, iii) the gum was soaked in hot water until it had 
completely dissolved and  the  liquid was  then allowed  to  cool and  carefully  strained before being 
used to bathe sore eyes or applied to burns,  iv) during smoky times, the  inner bark was soaked  in 
water, then placed over the eyelids whilst sleeping to relieve pain and inflammation, v) the bark was 
pounded, then boiled in water, allowed to cool, strained and used to bathe running sores and ulcers, 










investigation  to  identify  bioactive  compounds.  Fresh  leaves  of  the  plant  were  then  sequentially 
extracted  with  DCM,  DCM:MeOH  (50:50)  and  MeOH.  The  MeOH  extract  showed  highest  anti‐



















solvents  from  low  to  high  polarity which were DCM, DCM:MeOH  (50:50)  and MeOH  in  order  to 































The DCM, DCM:MeOH  (50:50) and MeOH extracts were  tested  in LPS +  IFN‐γ  induced RAW 264.7 
macrophages to obtain IC50 values for NO and TNF‐α down regulation and also LC50 for cytotoxicity. 
Due to low solubility of the extracts in the cell culture media, they were diluted in DMSO, leading to 
















DCM  9.07 ± 1.0  34.47 ± 14.7  42.49 ± 3.5 
DCM:MeOH (50:50)  9.63 ± 0.9  55.55 ± 29.6    62.49 ± 21.1 












































































95.74 ± 14.4  51.56 ± 4.6  > 36  144.5 



















to  suppress NO or TNF‐α production with  IC50 values 95.74 and 51.56 µg/mL  respectively  in LPS + 
IFN‐γ  induced  RAW  264.7 macrophages.  Therefore, we  did  not  give much  effort  to  re‐purify  the 
compound and moved to our next potent extract. 
Reason for missing mass of the materials 
We  found  only  one major  peak  (fraction  3  or  compound  3a.1,  Figure  3a‐5)  after  optimizing  the 
reverse‐phase HPLC method for sequential MeOH extract obtained from E. bosistoana. We tried to 













Dichloromethane  and  methanol  were  supplied  by  Merck.  Ethyl  acetate  from  Fisher  Chemical, 
ethanol  from  Chem‐Supply  and  water  used  was  Milli‐Q  water.  Bovine  serum  albumin, 
lipopolysaccharide (E. coli serotype‐0127:B8), EDTA, N‐(1‐napthyl) ethylenediamine dihydrochloride, 
benzylpenicillin G sodium salt, resazurin sodium salt (10%), streptomycin, sulphanilamide, 3,3′,5,5′‐





were purchased  from Life Technologies  (Mulgrave, VIC, Australia). Murine  interferon‐γ  (IFN‐γ) and 
TNF‐α ELISA kits were purchased from PeproTech Asia (Rehovot, Israel). Citric acid and monosodium 
dihydrogen  carbonate  (NaH2CO3) were  from AJAX  Chemicals  (Auburn, NSW, Australia).  Tween‐20 
was  from  Amresco  (Solon,  Ohio,  USA). Methanol, monosodium  phosphate  (NaH2PO4),  disodium 
phosphate (Na2HPO4), sodium chloride (NaCl) and sulfuric acid (H2SO4) were from Merck (Darmstadt, 














from  the  ‘Australian Botanic Gardens’ at Mount Annan, NSW, Australia. A voucher  specimen was 
deposited at the National Herbarium of NSW, Australia. 
3a.4.4 Extraction and isolation 
Approximately 200 g of  fresh  leaf material  from E. bosistoana was  first cut  into small pieces with 
scissors and  then ground  to a coarse powder using a hand blender. The coarse powder was  then 
filled  into  the thimbles of an accelerated solvent extraction system  (Buchi B‐811, Switzerland) and 
extracted  under  standard  Soxhlet  mode  (for  2  ×  15  minutes  cycles)  using  three  solvents 
(dichloromethane, dichloromethane and methanol  in 50:50  ratio and methanol)  sequentially  from 
low to high polarity. The volume of the extracts were reduced to a volume of 2—4 mL using a rotary 
evaporator  and  then  evaporated  to  dryness with  nitrogen.  The  sequential methanol  extract was 
found  most  potent  when  screened  for  anti‐inflammatory  activity.  This  crude  extract  was  then 
resuspended  in methanol  and  subjected directly  through  reversed phase  semi‐prep HPLC  (Phenyl 
column,  250  x  10  mm,  5μm;  Merck).  Peak  detection  was  performed  with  a  photodiode  array 
detector (PDA) using three detection wavelengths (210 nm, 254 nm and 290 nm). A gradient starting 
from 10% methanol/water to a 100% methanol (with a constant 0.01% formic acid modifier) over 20 
min and held at 100% methanol  for 20 min  to yield  compound 3a.1  (tR = 18.2 min, 2.5 mg). The 
isolated  compound was purified  to 95% purity or more as  judged by HPLC  (UV detection) and  1H 
NMR spectroscopy before determining the bioactivity. 





may  cause  degradation  of  our  compounds  of  interest.  Therefore,  we  compared  HPLC 
chromatograms of  two  types of samples obtained  from Sohxlet extraction and extraction at  room 
temperature keeping other parameters fixed. In this experiment, we found the HPLC chromatograms 
were overlapping considering  the number of peaks  in both modes but  the yield of extraction was 










concentrated by centrifugation  for 3 min at 900  rpm and  resuspended  in a  small volume of  fresh 
DMEM (with 1% antibiotics and 5% FBS). Cell densities were estimated using a Neubauer counting 
chamber.  The  cell  concentration was  adjusted with  DMEM  (with  1%  antibiotics  and  5%  FBS)  to 



















Nitric oxide was determined by Griess  reagent quantification of nitrite, one of  its  stable  reaction 
products. Griess  reagent was  freshly made  up  of  equal  volumes  of  1%  sulphanilamide  and  0.1% 
naphthylethylene‐diamine  in 5% HCl.  In  the presence of nitrite  this  reagent  forms a violet colour. 
From each well, 50 μL of supernatant was transferred to a fresh 96‐well plate and mixed with 50 μL 








The  Alamar  blue  assay  is  a  colorimetric  assay  involving  the  cellular  reduction  of  resazurin  to 




















constructed  with  defined  concentrations  of  TNF‐α.  Curve  fitting  of  this  standard  curve  and 
extrapolation of experimental data were performed using non‐linear regression analysis.  
3a.4.10 Data presentation and analysis 
For  sequential extracts,  three experiments  in quadruplicates  (n=12) were  combined  to determine 
the IC50 (for NO inhibition) and LC50 (for cell viability) whereas one experiment in triplicate (n=3) was 
conducted  to  obtain  IC50  for  TNF‐α  inhibition  using  the  dose‐response  inhibition  function  in 
GraphPad Prism version 6.01 (GraphPad Software Incorporated, USA). For purified compounds, two 









































Screening of Plants used in Australian 














The  process  of  inflammation  is  defined  as  a  sequence  of  events  that  takes  place  in  response  to 
foreign stimuli, trauma or  infection and  is characterized by redness, heat, swelling,  loss of function 




oxidative  stress, which  contributes  to  the  progression  of  atherosclerosis,  diabetes  and metabolic 
syndrome, multiple sclerosis, Parkinson’s and Alzheimer’s disease [5‐7].  
Drugs  can  cause  potential  harms  beside  their  beneficial  activities  [8].  Non‐Steroidal  Anti‐
inflammatory  Drugs  (NSAIDs)  are most  commonly  prescribed  anti‐inflammatory medication  and 
many individuals may be susceptible to a number of side effects, gastrointestinal complication being 
the most  frequent.  Corticosteroids  on  the  other  hand  are  highly  effective  at  controlling  chronic 
inflammation by  suppressing  the  immune  response but  can  give  rise  to  a number of  side  effects 
including weight gain, osteoporosis, thinning and bruising of skin amongst others [9,10]. 
Plants  having  medicinal  values  are  recognised  as  the  oldest  and  most  widespread  form  of 
medication  throughout  the world. Plant derived natural products have proven  to be an  important 
source  of  active  ingredients  in  pharmaceutical  preparations,  setting  the  foundation  of  the 
pharmaceutical  industry,  while  in more  recent  times  synthetic  compounds  are  used  in modern 
formulations [11].    Salicylic acid  is an active ingredient of willow bark, while the  introduction of its 
synthetic analogue (aspirin)  in 1897 was a breakthrough for the treatment of various  inflammatory 
disorders [12].  
The  diverse  Australian  flora  in  association  with  their  more  than  40,000  years  old  Indigenous 
medicinal knowledge provides great scope to select novel plants for health enhancing properties. It 
is  already  demonstrated  that many  of  the  plants  used  by  native  Australians  contain  important 
biologically  active molecules  [13,14].  Clerodane  diterpenoid  compounds  isolated  from  Dodonaea 
polyandra, which  is a native Australian plant, were found to inhibit pro‐inflammatory cytokines like 
IL‐1β and  IL‐6  [15,16].  In another  investigation, anti‐inflammatory agarofurans have been  isolated 
from the seeds of the Australian rainforest vine Celastrus subspicata [17]. Six steroids isolated from 















genera and 8 different  families  to evaluate  their  anti‐inflammatory activity.  LC‐MS profiles of  the 





In  this  study,  leaves  from  15  different  plants  were  collected  in  the  month  of  July,  2016. 
Approximately  20g  of  leaves  from  each  of  Acacia falcata,  A.  leprosa,  A.  melanoxylon, 
Adiantum formosum, Asplenium australasicum, A.  flavelifolium, Baeckea  imbricata, B.  ramosissima 




and  this  principle  has  become  an  established  experimental  model  to  evaluate  in  vitro  anti‐
inflammatory activity of extracts [14,22‐24]. For the purpose of interpretation, the IC50 values of NO 




µg/mL  with  serial  ½  dilutions.  Syncarpia  glomulifera  subsp.  glomulifera,  Melaleuca  linariifolia,  
Baeckea  ramosissima  subsp.  ramosissima  and  B.  imbricata  leaf  extracts  showed  the  strongest 
inhibition  of  NO  production with  IC50  values  of  8.25,  9.74,  15.68  and  16.78    µg/mL  respectively 
(Figure 4‐1, Table 4‐4). The extracts  from Acacia melanoxylon, Pimelea  linifolia, Acacia  leprosa and 
Pittosporum undulatum showed moderate  inhibition of NO with  IC50 values of 28.94, 30.36, 35.49 
and 66.36 µg/mL respectively. The remaining seven plants, Telopea speciossissima, Hakea salicifolia, 
Acacia falcata,  Mentha  satureioides,  Adiantum formosum,  Asplenium  flavelifolium  and  A. 
australasicum presented  low  inhibition of NO with  IC50 values of 116.5, 195.9, 215.5, 218.7, 238.0, 
280.3 and 503.3 µg/mL respectively. 
Four of the plant extracts also showed promising TNF‐α inhibitory activity (Figure 4‐1, Table 4‐4) with 
IC50  values  of  23.30,  16.40,  8.31  and  22.77  μg/mL  for  Syncarpia  glomulifera  subsp.  glomulifera, 
Melaleuca linariifolia,  Baeckea ramosissima subsp. ramosissima and B. imbricata respectively, which 
are  the  same plants  in our highly potent NO  inhibitor group. On  the other hand,  the moderately 
active  extracts  from  Acacia melanoxylon,  Pimelea  linifolia,  Acacia  leprosa  and  Pittosporum 
undulatum showed TNF‐α  IC50 value of 68.20, 49.70, 63.05 and 66.14 μg/mL respectively. Whereas 
extracts  from  Telopea  speciossissima,  Hakea  salicifolia,  Acacia falcata,  Mentha  satureioides, 
Adiantum formosum,  Asplenium  flavelifolium  and  A.  australasicum  exhibited  lower  to moderate 





The  use of Alamar Blue  (rezazurin)  to measure  cytotoxicity  is  an  established  technique  [25].  The 
results of cytotoxicity (LC50) of our leaf extracts are shown in Table 4‐4 and Figure 4‐1. The plants of 
our highly potent group showed moderate toxicity with LC50 values of 52.09, 101.6, 85.68, and 130.0 
μg/mL  for  Syncarpia  glomulifera  subsp.  glomulifera, Melaleuca  linariifolia,  Baeckea  ramosissima 
subsp.  ramosissima  and  B.  imbricata  respectively.  Plants with moderate  potency  showed  a wide 
range of  toxicity with LC50 values of 36.26, 226.3, 103.9, and 108.1 μg/mL  for Acacia melanoxylon, 
Pimelea  linifolia, Acacia  leprosa  and  Pittosporum  undulatum  respectively.  The  plants  of  the  least 




In our LC‐MS study of  the  leaf extracts, polar compounds were detected  in  the early phase of  the 
separation and non‐polar compounds were detected in the later phase. Interestingly, extracts rich in 





and  screened.  The plants  studied here were  chosen on  the basis of  their  traditional use  to  treat 
inflammatory  and  related  conditions  by  the  D’harawal  people  of  the  Campbelltown  region 
(Southwest Sydney Australia). Most of the plants showed anti‐inflammatory activity, demonstrated 
inhibitory effect on NO and TNF‐α production with varying potencies, which provides some evidence 
supporting  their  use  in  traditional  Aboriginal  medicine.  The  amount  of  the  anti‐inflammatory 
compounds  in  the plants  ‐  according  to  traditional  knowledge  ‐  is  also dependent on  the plant’s 
environment. In D’harawal country, what is most important when seeking particular medicines from 
plants  is where  the plant  is growing,  that  is, not  so much  the  soils, but  the other plants  that are 
growing  around  the  particular  plant  required  [26].  For  the  present  screening  study,  the  plant 
material was provided by  the Botanical Gardens  from  random  trees  in  the garden, but  for  future 
studies, we will  investigate  if  traditional  collection  practices  based  on  D’harawal  knowledge will 
improve the inherent activity and/or yield of the anti‐inflammatory compounds.  
We  also  obtained  LC‐MS  profile  of  the  15  extracts.  Since,  chemical  profiling  of  plant  secondary 
metabolite  has  the  potential  to  generate  structural  information  [27]  and  liquid  chromatography 
coupled to mass spectrometry has emerged as a key technology for broad screening of biomolecular 
components  across multiple  samples  (corresponding  to different  condition,  interventions  or  time 
points [28‐30]. 
In our LC‐MS study of  the  leaf extracts, polar compounds were detected  in  the early phase of  the 
separation and non‐polar compounds were detected in the later phase. Interestingly, extracts rich in 










(Mrs.  Frances  Bodkin)  and  following  the  D’harawal  Pharmacopeia.  Leaf materials  of  15  selected 




Ethanol  was  purchased  from  Chem‐Supply  (Gillman,  SA,  Australia),  Bovine  serum  albumin, 
lipopolysaccharide  (E.  coli  serotype‐0127:B8),  EDTA,  N‐(1‐napthyl)  [2]  ethylenediamine 
dihydrochloride,  benzylpenicillin  G  sodium  salt,  resazurin  sodium  salt  (10%),  streptomycin, 
sulphanilamide, 3,3′,5,5′‐tetramethylbenzidine  (TMB),  trypan blue and Dulbecco’s Modified Eagle’s 
Medium  (DMEM) were  purchased  from  Sigma‐Aldrich  (Castle Hill, NSW, Australia).  Foetal  bovine 
serum  (FBS)  and  glutamine  were  purchased  from  Life  Technologies  (Mulgrave,  VIC,  Australia). 
Murine  interferon‐γ  (IFN‐γ)  and  TNF‐α  ELISA  kits were purchased  from  PeproTech Asia  (Rehovot, 
Israel).  Citric  acid  and monosodium  dihydrogen  carbonate  (NaH2CO3) were  from  AJAX  Chemicals 
(Auburn, NSW, Australia). Tween‐20 was from Amresco (Solon, Ohio, USA). Methanol, monosodium 
phosphate  (NaH2PO4),  disodium  phosphate  (Na2HPO4),  sodium  chloride  (NaCl)  and  sulfuric  acid 














factor  x  4)  using  a method  run  time  of  35 min  and  solvent  flow  rate  of  0.2 mL/min.  Solvent  A 
consisted of 0.1% (v/v) formic acid in ultrapure water and solvent B was 0.1% (v/v) formic acid in LC‐
MS  grade  acetonitrile.  The  chromatographic method  consisted  initially  of  10%  solvent  B  ramped 
linearly  to 95% solvent B over 20 min. At 25 min,  the solvent composition  returned  to 10% B and 











was 30  kV. Positive  and negative  spectra were  recorded  simultaneously over  the m/z  range 100‐






























Nitric oxide was determined by Griess  reagent quantification of nitrite, one of  its  stable  reaction 
products.  Griess  reagent  was  freshly made  up  of  equal  volumes  of  1%  sulfanilamide  and  0.1% 





of  Griess  reagent,  and  the  colour  produced  was  measured  at  540  nm  in  a  microplate  reader 




The  Alamar  blue  assay  is  a  colorimetric  assay  involving  the  cellular  reduction  of  resazurin  to 


















Omega  microplate  reader  (BMG  Labtech,  Mornington,  Australia).  The  absorbance  data  was 
expressed as a percentage of that of control wells after conversion of the concentrations by using a 















No.  Plant  APNI name  Family  Voucher No. 
1  Acacia falcata  Acacia falcataWilld. Fabaceae/Mimosaceae 20041358
2  Acacia leprosa  Acacia leprosa Sieber ex DC.  Fabaceae/Mimosaceae  AA 20150001 
3  Acacia melanoxylon  Acacia melanoxylon R.Br.  Fabaceae/Mimosaceae  20040377 
4  Adiantum formosum  Adiantum formosum R.Br.  Adiantaceae  882136 
5  Asplenium australasicum  Asplenium australasicum (J.Sm.) Hook.  Aspleniaceae 20120611
6  Asplenium flavelifolium  Asplenium flavelifolium Cav.  Aspleniaceae  20120621 
7  Baeckea imbricata  Baeckea imbricata (Gaertn.) Druce  Myrtaceae  AC 942545 
8  Baeckea ramosissima subsp. ramosissima Baeckea ramosissima A.Cunn. subsp. ramosissima. Myrtaceae AD 823136
9  Hakea salicifolia  Hakea salicifolia (Vent.) B.L.Burtt.  Proteaceae  AA 873438 
10  Melaleuca linariifolia  Melaleuca linariifolia Sm.  Myrtaceae  AA 922868 
11  Mentha satureioides  Mentha satureioides R.Br.  Lamiaceae  20021036 
12  Pimelea linifolia  Pimelea linifolia Sm..  Thymelaeaceae  AF 933363 
13  Pittosporum  undulatum  Pittosporum undulatum Vent.  Pittosporaceae 20000309
14  Syncarpia glomulifera subsp. glomulifera  Syncarpia glomulifera (Sm.) Nied. subsp. glomulifera.  Myrtaceae  891962 




























































At  certain  times of  the year and under  certain  conditions, parts of  this plant were  collected,  then  treated and used as a  treatment  for 
cancerous growths. 
Pittosporum  undulatum 






























Syncarpia glomulifera subsp. glomulifera  8.25 ± 1.1  23.30 ± 3.4  52.09 ±  20.9   
Melaleuca linariifolia  9.74 ± 2.0  16.40 ± 2.9  101.6 ± 13.5   
Baeckea ramosissima subsp. ramosissima  15.68 ± 1.6  8.31 ± 3.3  85.68 ± 19.8   






Acacia melanoxylon  28.94 ± 5.0  68.20 ± 9.5  36.26 ± 7.2   
Pimelea linifolia  30.36 ± 2.9  49.70  ± 9.9  226.3 ± 46.9   
Acacia leprosa  35.49 ± 4.4  63.05 ± 13.4  103.9 ± 16.4   








Telopea speciossissima  116.5 ± 20.1  555.1 ± 87.5  > 900  63.15 
Hakea salicifolia  195.9 ± 30.7  697.7 ± 185.3  > 900  149.93 
Acacia falcata  215.5 ± 31.1  133.60 ± 38.6  > 900  212.00 
Mentha satureioides  218.7 ± 20.8  62.75 ± 11.4  242.4 ± 88.7   
Adiantum formosum  238.0 ± 46.8  86.65 ± 39.9  > 900  71.92 
Asplenium flavelifolium 280.7 ± 57.5 62.07 ± 28.0 > 900 190.01
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Anti-inflammatory Flavonoids and 













The plant  family Myrtaceae  is comprised of 130 genera, which contain more  than 3000 species being 
predominantly distributed  in tropical, subtropical, and temperate regions of the world [1].  In Australia 
Melaleuca  (Myrtaceae)  is  considered  to  be  the  third  most  diverse  plant  genus  after  Acacia  and 
Eucalyptus which represents 250 species many being undescribed. As stated in the literature, all known 
Melaleuca species are native to Australia and all except nine are endemic [2,3]. 
Melaleuca  linariifolia  is a tree up to 10 m high, cultivated  in Australia [4]. It was an  important plant to 






A  number  of  phytochemical  studies  carried  out  on  Melaleuca  species  indicate  the  presence  of 
phenylpropanoids  (methyl  eugenol,  (E)‐methylisoeugenol),  monoterpenoids  (mainly,  1,8‐cineole, 
terpinen‐4‐ol,terpinolene,  along  with  p‐cymene,  α‐terpinene,  α‐terpineol,  α‐pinene),  and 
sesquiterpenoids (nerolidol, viridiflorol, ledol, β‐caryophyllene etc.) as the major constituents  [5‐11] 
In  this  study,  the crude EtOH  leaf extract of M.  linariifolia exhibited  strong anti‐inflammatory activity 
(IC50 = 9.74 μg/mL for NO inhibition) in LPS + IFN‐γ activated 264.7 RAW macrophages and was selected 





























































The n‐hexane, DCM, EtOAc, EtOH, MeOH and water extracts were  tested  in LPS +  IFN‐γ  induced RAW 
264.7  macrophages  to  obtain  IC50  values  for  NO  and  TNF‐α  down  regulation  and  also  LC50  for 
cytotoxicity. Due to  low solubility of the extracts  in the cell culture media, they were diluted  in DMSO, 
leading to a final concentration of up to 0.5% DMSO in cell culture medium. This concentration of DMSO 
showed  a  cell  viability  of  less  than  10%  (data  not  shown).  All  six  sequential  extracts  demonstrated 
significant anti‐inflammatory activity, reducing NO production which was  less  than 32 µg/mL. The  IC50 
obtained  for  the  inhibition  of  TNF‐α  production  ranged  between  19  –  176  µg/mL whereas  LC50  for 
cytotoxicity exhibited values between 38 – 381 µg/mL (Figure 5‐3 and Table 5‐2). The sequential EtOAc 












n‐Hexane  30.15 ± 4.0  110.20 ± 44.8  221.70 ± 17.2 
DCM  31.28 ± 4.0  176.20 ± 90.0  229.10 ± 22.6 
EtOAc  3.96 ± 0.5  19.39 ± 7.2  48.66 ± 3.0 
EtOH  7.16 ± 0.9  29.91 ± 9.9  76.21 ± 8.6 
MeOH  20.70 ± 2.7  67.26 ± 24.1  38.84 ± 4.7 








Figure  5‐3.  Inhibition  of  LPS  and  IFN‐γ  induced  NO  and  TNF‐α  production  and  cell  viability  of  M. 







In  order  to  identify  bioactive  compounds,  the  sequential  EtOAc  extract  (IC50  =  3.96  μg/mL  for  NO 



















































signals  assigned  from  HSQC  and  HMBC  spectra  (Table  5.1.bSI)  revealed  that  compound  5.1  was  a 
3,3',4',5,7‐pentahydroxyflavan.  A  coupling  constant  of  13.0  Hz  between  H‐2  and  H‐3  suggested  that 













J  =  3.6) which were  indicative  of  H‐2,  H‐3,  H‐4a  and  H‐4b  respectively.  The  1H NMR  spectrum  also 
exhibited three meta‐coupled doublets at Hδ 6.65 (2H, d, J = 2.7 Hz) indicative of H‐2', H‐6' and 6.88 (1H, 
d,  J = 2.4 Hz)  indicative of H‐4', which were attributable to a 3',5' disubstituted B ring of  flavane. Two 
meta‐coupled doublets at Hδ 5.88 (1H, d, J = 2.4 Hz) and 5.71 (1H, d, J = 2.4 Hz), indicative of H‐6 and H‐8 
were consistent with a 5,7‐dioxygenated A ring of flavan. These proton resonances together with their 










Compound 5.3 was obtained as white amorphous powder. The HR‐ESI‐MS  (positive  ion mode) of  this 
compound  revealed a quasi‐molecular  ion peak at m/z 479.3513  [M+Na]+  (calculated  for C30H48O3Na, 






















and  39.69  µg/mL  respectively  for  NO  inhibition  and  58.88  and  80.70  µg/mL  for  TNF‐α  inhibition 
respectively.  Both  of  the  compounds  did  not  show  any  toxicity  up  to  the  highest  concentration  (36 
µg/mL)  tested. On  the  other  hand,  compound  5.3  exhibited  strong  activity  for  both  NO  and  TNF‐α 
inhibition with IC50 values of 2.73 and 4.11 µg/mL respectively and an LC50 value of 9.86 µg/mL. 
In N11 microglia,  compound 5.1 and 5.2 were also moderate  to down  regulating of NO and  the  IC50 
values were 66.25  and 58.05 µg/mL but both  compounds were  found  to be more effective  to down 
regulate TNF‐α with IC50 values of 17.34 and 21.84 µg/mL respectively. Both of the compounds did not 














5.1  72.81 ± 37.9  58.88 ± 35.9  > 36  128.5 
5.2  39.69 ± 11.5  80.70 ± 50.1  > 36  131.8 













































































5.1  66.27 ± 31.3  17.34 ± 3.3  > 36  113.0 
5.2  58.05 ± 30.1  21.84 ± 3.6  > 36  129.0 
5.3  2.23 ± 0.4    6.76 ± 1.4  11.01 ± 1.4   
 
Compound 5.1_N11























































Figure 5‐5. Down  regulation of  LPS  and  IFN‐γ  induced NO  and  TNF‐α production  and  cell  viability of 







Compound  5.1  has  four  epimers  [13]  commonly  known  as  catechin  and  are  reported  to  have  anti‐




Compound 5.2  is a  constitutional  isomer of  compound 5.1 and  reported  to have anti‐oxidant activity 
[18]. The anti‐inflammatory activity of compound 5.2 is being reported for the first time. However, this 
compound  is  moderately  active  in  both  cell  lines  under  investigation,  with  an  exception  to  down 
regulate TNF‐α in N11 microglia which was strong with an IC50 value of 21.84 μg/mL. 
Compound 5.3 is a widely studied compound and is reputed for many biological activities including anti‐
inflammatory  activity  [20,29‐33].  In  our  study,  we  also  found  this  compound  is  very  strong  to 
downregulate NO and TNF‐α  in LPS + IFN‐γ induced RAW macrophages with IC50 values of 2.73 and 4.11 
μg/mL  respectively  as well  as  in N11 microglia with  IC50  values of  2.23  and  6.67  μg/mL  respectively. 




















n‐Hexane  33.17  9.07  66.67  18.24 
Dichloromethane  31.97  5.68  188.94  33.54 
Ethyl acetate  252.53  51.57  858.59  175.35 
Ethanol  139.66  33.43  1634.08  391.17 
Methanol  48.31  14.87  491.79  151.35 































25.20  12.39  0.10  0.05 






The potency  (for NO and TNF‐α  inhibition) of each of the sequential extracts and  isolated compounds 
from M. linariifolia leaves were measured as a reciprocal of IC50 value (Table 5‐5 and 5‐6). The total anti‐
inflammatory activity  for both NO and TNF‐α  inhibition  (Table 5‐5 and 5‐6) of  the  same extracts and 
compounds  were  also  obtained  by  multiplying  respective  potency  and  yield  of  dried  extracts  and 
isolated compounds. Thus the total anti‐inflammatory activity of all extracts was found to be 3357.59 L 
for NO  inhibition  in 130 g  leaves of M.  linariifolia of which 0.09 L, 0.10 L and 2.29 L were obtained by 
catechin  (5.1),  3,3’,5,5’,7‐pentahydroxyflavan  (5.2)  and  betulinic  acid  (5.3)  respectively.  Similarly,  the 









Acetonitrile,  n‐hexane,  dichloromethane  and methanol were  supplied  by Merck.  Ethyl  acetate  from 
Fisher Chemical, ethanol from Chem‐Supply and water used was Milli‐Q water. Bovine serum albumin, 
lipopolysaccharide  (E.  coli  serotype‐0127:B8),  EDTA,  N‐(1‐napthyl)  ethylenediamine  dihydrochloride, 
benzylpenicillin  G  sodium  salt,  resazurin  sodium  salt  (10%),  streptomycin,  sulphanilamide,  3,3′,5,5′‐
tetramethylbenzidine  (TMB),  trypan  blue  and  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  were 





ELISA  kits  were  purchased  from  PeproTech  Asia  (Rehovot,  Israel).  Citric  acid  and  monosodium 
dihydrogen  carbonate  (NaH2CO3) were  from AJAX Chemicals  (Auburn, NSW, Australia). Tween‐20 was 
from Amresco  (Solon, Ohio, USA). Methanol, monosodium phosphate  (NaH2PO4), disodium phosphate 




spectra were  obtained  on  a  Bruker  Ascend  400 MHz  spectrometer  (Bruker  Biospin  GmbH,  Bremen, 
Germany).   TopSpin software was used to analyse the spectral data. 1H NMR spectra were recorded at 
400 MHz.  The  chemical  shifts  (δ)  are  expressed  in  parts  per million  (ppm)  as  δ  values  and  coupling 
constant J in Hertz (Hz). COSY, HSQC and HMBC were acquired using the standard Bruker pulse program. 
The  experiments  were  performed  in  dimethyl  sulfoxide‐d6  (DMSO‐d6)  and  chemical  shifts  were 
calibrated relative to the DMSO solvent peak (1H δ at 2.50 and 13C δ 39.51 ppm). High resolution mass 
spectrometry  (HRMS)  was  carried  out  using  a Waters  Xevo  Q‐TOF mass  spectrometer  operating  in 
positive electrospray ionization (ESI) mode. 
5.4.3 Plant material 






thimbles of  an  accelerated  solvent extraction  system  (Buchi B‐811,  Switzerland)  and  extracted under 
standard Soxhlet mode (for 2 × 15 minutes cycles) using six solvents (n‐hexane, dichloromethane, ethyl 
acetate, ethanol, methanol and water) sequentially from low to high polarity. The volume of the extracts 
was  reduced  to a volume of 2—4 mL using a  rotary evaporator and  then evaporated  to dryness with 
nitrogen.  The  sequential  ethyl  acetate  extract  was  found  most  potent  when  screened  for  anti‐
inflammatory  activity.  This  crude  extract was  then  resuspended  in methanol  and  subjected  directly 
through  reversed  phase  semi‐prep  HPLC  (Phenyl‐Hexyl  column,  250  x  10 mm,  Phenomenex).  Peak 
detection was performed with a photodiode array detector  (PDA) using  three detection wavelengths 
(210 nm, 254 nm and 290 nm). A gradient starting from 20% methanol/water to a 100% methanol (with 
a  constant 0.01%  formic  acid modifier) over 50 min  and held  at 100% methanol  for 10 min  to  yield 








RAW  264.7 macrophages  and  N11 microglial  cells were  grown  in  175  cm2  culture  flasks  on  DMEM 
(Dulbecco’s Modified Eagle’s Medium) containing 5% FBS (foetal bovine serum) that was supplemented 
with  penicillin  (100  U/mL),  streptomycin  (100  μg/mL)  and  glutamine  (2  mM).  The  cell  line  was 
maintained  in  5% CO2  at  37  °C, with media being  replaced  every  3‐4 days. Once  cells had  grown  to 
confluence in the culture flask, they were removed using a rubber policeman cell scraper, as opposed to 
using trypsin, which can remove membrane‐bound receptors. The cell suspension was concentrated by 
centrifugation  for  3 min  at  900  rpm  and  resuspended  in  a  small  volume  of  fresh  DMEM  (with  1% 
antibiotics  and  5%  FBS).  Cell densities were  estimated using  a Neubauer  counting  chamber.  The  cell 
concentration was adjusted with DMEM (with 1% antibiotics and 5% FBS) to obtain 60,000 cells/100 µL 





with extracts, a 90  μL volume of  the dilutions  in DMEM  (with 0.1% FBS) was added an hour prior  to 
addition of the activator. Due to the often inconsistent nature of LPS at activating cells, a combination of 
LPS (10 μg/mL) and IFN‐γ (10 U/mL), both  in DMEM (with 0.1% FBS), were used for activation. For the 






control and activated  cells used as positive  control. The effects of  solvents on  readouts were  initially 
determined, but as  the anti‐inflammatory or cytotoxic effects of  the solvents were < 10% even at  the 
highest concentration used, parameters were compared to the “no solvent” controls. 
5.4.7 Determination of nitric oxide production by Griess assay 
Nitric  oxide  was  determined  by  Griess  reagent  quantification  of  nitrite,  one  of  its  stable  reaction 
















The  results were expressed as a percentage of  the  intensity of  that  in  control  cells after background 
fluorescence was subtracted. 
5.4.9 TNF‐α determination by ELISA 
The  supernatants  obtained  from  each well  (remaining  supernatant  after  24  hours  of  activation)  and 
experiment that gave better readout for NO and Alamar blue assay were used for determination of TNF‐
α  using  a  commercial  sandwich  ELISA  (Catalog  number:  900‐K54;  Peprotech,  USA)  according  to  the 
manufacturer’s protocol. The supernatants were diluted 30 times using diluent (0.1% w/v bovine serum 
albumin and 0.05% v/v  tween‐20  in PBS  [1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 154 mM NaCl; pH7.4]).  
Capture antibody was used at a concentration of 1.25 μg/mL  in PBS. To make a standard curve TNF‐α 
(10 ng/mL standard) was diluted serially by 50% up to a minimum of 10 doses (10, 5, 2.5, 1.25, 0.625, 










For  sequential extracts,  three experiments  in quadruplicates  (n=12) were combined  to determine  the 
IC50  (for  NO  inhibition)  and  LC50  (for  cell  viability)  whereas  one  experiment  in  triplicate  (n=3)  was 
conducted  to obtain  IC50  for TNF‐α  inhibition using  the dose‐response  inhibition  function  in GraphPad 
Prism version 6.01 (GraphPad Software Incorporated, USA). For purified compounds, two experiments in 
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Anti-inflammatory Molecules from Syncarpia 

























Isolation  of  anti‐bacterial  and  cytotoxic  triterpenoids  from  the  bark  extract  of  the main  species  S. 
glomulifera  from  Paluma, North Queensland,  Australia  has  been  previously  reported  [2].  In  another 
study, the anti‐plasmodial compound phloroglucinol has been isolated from the same species [3]. 
The  crude  EtOH  extract  of  the  leaf  of  S.  glomulifare  subsp.  glomulifera  exhibited  strong  anti‐
inflammatory  activity  (IC50  =  8.25  μg/mL  for  NO  inhibition)  in  LPS  +  IFN‐γ  activated  264.7  RAW 
macrophages and was  selected  for  investigation  to  identify bioactive compounds. The  fresh  leaves of 
the  plant  were  then  sequentially  extracted  with  n‐hexane,  DCM,  EtOAc,  EtOH,  MeOH  and  water. 





The  bioassay‐guided  fractionation  of  the  extract  led  to  the  isolation  of  two  new  and  three  known 
compounds, 6.1 ‐ 6.5. The structure of 6.1 was elucidated based on its analyses of MS data, 1D, 2D NMR 
data  as well  as  by  comparison  of  literature  data  of  the  known  analogues.  The  structure  of  6.4 was 




IC50 values of 3.91, 35.15, 2.67, 29.42 and 7.84 µg/mL,  respectively  in down  regulating NO, while  IC50 
values in down regulating TNF‐α were 16.90, 32.12, 20.80, 37.57 and 33.35 µg/mL, respectively in LPS + 
IFN‐γ activated 264.7 RAW macrophages. Compound 6.1 and 6.3 did not show any toxicity up to the 2nd 
highest  concentration  tested  (>  18  µg/mL), whereas  compound  6.2,  6.4  and  6.5  did  not  show  any 
toxicity with the highest concentration tested (> 36 µg/mL). 
In  LPS  +  IFN‐γ  activated N11 microglia,  compound 6.1 6.2, 6.3, 6.4  and 6.5  gave  IC50  values of 4.52, 
21.17,   3.87, 39.64 and 4.51 µg/mL for NO suppression and IC50 values for TNF‐α downregulation were 
6.50, 27.01, 13.66, 33.06 and 5.46 µg/mL respectively. LC50 values for cell viability were 24.31 and 19.05 






















































































The n‐hexane, DCM, EtOAc, EtOH, MeOH and water extracts were  tested  in LPS +  IFN‐γ  induced RAW 
264.7  macrophages  to  obtain  IC50  values  for  NO  and  TNF‐α  down  regulation  and  also  LC50  for 
cytotoxicity. Due to  low solubility of the extracts  in the cell culture media, they were diluted  in DMSO, 
leading to a final concentration of up to 0.5% DMSO in cell culture medium. This concentration of DMSO 




















n‐Hexane  7.40 ± 0.7  32.08 ± 4.2  18.31 ± 3.3 
DCM  7.64 ± 0.6  32.61 ± 5.7  28.88 ± 2.6 
EtOAc  4.72 ± 0.4  24.06 ± 3.7  16.22 ± 2.0 
EtOH             15.90 ± 1.3    177.6 ± 23.4    88.49 ± 13.5 
MeOH             73.95 ± 7.6    271.6 ± 32.6  244.80 ± 49.4 



















glomulifera  subsp.  glomulifera  sequential  extracts  in  RAW  264.7 macrophages.  Data  represented  as 
three experiments  in quadruplicates  (n=12, mean ± SEM). *One experiment  in  triplicate  (n=3, mean ± 
SEM). 
6.2.3 Isolation of active compounds 





































Compound  6.1 was  isolated  as  a  yellowish  solid. HRESI  (+) MS  analysis  of  compound  6.1  revealed  a 
pseudomolecular  ion  ([M  + Na]+)  indicative of  a molecular  formula  (C25H32O6Na)  requiring  10 double 


















the  cinnamoyl  ester  group.  The  side  chain  moiety  of  compound  6.1  at  C‐6  was  assigned  as  an 
isobutylene  group  due  to  the  deshielded  chemical  shift  of H‐1”  (Hδ  5.59,  1H,  brs)  along with HMBC 
correlation of H‐1” to C‐6 (Cδ 77.8), C‐2”( Cδ 138.8), C‐3” (Cδ 18.8), C‐4”( Cδ 26.5) and C‐1. Identifications 
and  placements  of  the  cinnamoyl  ester,  isobutylene  and  acetyl  groups  were  confirmed  by  HMBC 
correlations (Figure 6.4) in addition to comparison of NMR data with those of related compounds [6,7].  
There were three stereo centers in the compound 6.1 at C‐3, C‐5 and C‐6. The 1H NMR spectrum of this 
compound  showed 2  singlets at Hδ 5.15 and 5.17  (each 1H, 3 and 5  respectively)  indicating  that  they 
were  not  coupled  to  any  other  proton. We  conducted  ROSEY  experiment  to  determine  the  relative 
stereochemistry  of  6.1 which was  also  not  helpful  due  to  the  presence  of  eight  densely  congested 
substituents  on  the  cyclohexanone  ring.  Therefore,  the  relative  stereochemistry  of  6.1  could  not  be 
















































3  5.15 s  77.4  2, 4, 5, 7, 8, 9, 10, 11 
4  ‐  39.2 
5  5.17 s  79.4  1, 3, 4, 6, 9, 10, 1’, 1” 
6  ‐  77.8 
7  1.10 s  26.3  1, 2, 3, 8 
8  1.23 s  22.5  1, 2, 3, 7 
9  0.94 s  24.5  3, 4, 5, 10 
10  1.21 s  22.3  3, 4, 5, 9 
11  ‐  170.5 
12  2.12 s  20.1  11 
1’  ‐  165.0 
2’  6.63 d(16.0)  117.2  3’  1’, 3’, 4’ 
3’  7.63 d(16.0)  144.5  2’  1’, 2’, 4’, 5’, 9’ 
4’  ‐  134.0 
5’  7.43 d(2.1)  128.5  6’  2’, 3’, 4’, 6’, 7’, 8’, 9’ 
6’  7.43 d(2.1)  130.3  5’, 7’  4’, 5’, 7’, 8’, 9’ 
7’  7.74 dd(5.6, 2.0)  127.5  6’, 8’  5’, 6’, 8’, 9’ 
8’  7.43 d(2.1)  130.3  7’, 9’  4’, 5’, 6’, 7’, 9’,  
9’  7.43 d(2.1)  128.5  8’  2’, 3’, 4’, 5’, 6’, 7’, 8’ 
1”  5.59 brs  121.7  6, 2”, 3”, 4” 
2”  ‐  138.8 
3”  1.69 s  18.8  1”, 2”, 4” 







Compound 6.2 was obtained as yellowish  solid.  Its  structure was elucidated as  the known compound 
tetragocarbone  B  (Figure  6‐2)  by  comparison  of  its  mass  spectrometry  and  NMR  dataSI  with  the 












lumaflavanone A, which we have also  isolated as our  compound 6.5. However a difference  from  the 
known derivative (lumaflavanone A) includes the presence of an aromatic proton at Hδ 6.46 as a singlet 
instead of a methyl group at C‐6 as evident from 1H NMR spectrumSI.  
Compound  6.4  was  found  to  have  an  optical  rotation  of  zero,  indicating  that  it  was  isolated  as  a 
racemate.  It  has  two  stereo  centers  at C‐2  and C‐9.  This optical  inactivity was  similar  to  that of  the 






































Compound 6.5 was  isolated  as  yellowish  solid.  Its  structure was  elucidated  as  the  known  compound 
lumaflavanone A (Figure 6‐2) by comparison of its mass spectrometry and NMR dataSI with the literature 
data [5].  





Compounds 6.1  ‐ 6.5 were evaluated  for anti‐inflammatory activity  in LPS +  IFN‐γ  induced RAW 264.7 
macrophages (Figure 6‐5 and Table 6‐5) and N11 microglia (Figure 6‐6 and Table 6‐6).  
In RAW 264.7 macrophages,  compounds 6.1  ‐ 6.5  showed  strong  anti‐inflammatory  activity with  IC50 
value  of  3.91  ±  0.5,  35.15  ±  7.3,  2.76  ±  0.3,  29.42  ±  2.7  and  7.84  ±  1.3  µg/mL  respectively  for NO 
inhibition and 16.90 ± 3.4, 32.12 ± 13.2, 20.80 ± 14.1, 37.57 ± 11.7 and 33.35 ± 3.8 µg/mL  for TNF‐α 























6.1  3.91 ± 0.5  16.90 ± 3.4  > 18  66.0 
6.2  35.15 ± 7.3  32.12 ± 13.2  > 36  82.5 
6.3  2.76 ± 0.3  20.80 ± 14.1  > 18  87.8 
6.4  29.42 ± 2.7  37.57 ± 11.7  > 36  140.5 
6.5  7.84 ± 1.3  33.35 ± 3.8  > 36  77.3 
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Figure 6‐5. Down  regulation of  LPS  and  IFN‐γ  induced NO  and  TNF‐α production  and  cell  viability of 
isolated compounds from Syncarpia glomulifera subsp. glomulifera in RAW 264.7 macrophages 












6.1  4.52 ± 0.8  6.50 ± 1.3  24.31 ± 6.1   
6.2  21.17 ± 3.8  27.01 ± 8.5  > 36  143.8 
6.3  3.87 ± 0.5  13.66 ± 3.8  19.05 ± 5.7   
6.4  39.64 ± 10.4  33.06 ± 5.9  > 36  155.8 
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Compound  6.1  is  reported  for  the  first  time  and  this  compound  demonstrated  very  promising  anti‐
inflammatory activity as evaluated against both LPS and IFN‐γ induced RAW 264.7 macrophage and N11 
microglial cell line.  
Compound 6.2  is reported by Nishimura et al  in 2016 but there  is no report on the anti‐inflammatory 
activity  of  compound  6.2.  In  our  study,  compound  6.2  exhibited  good  anti‐inflammatory  activity  as 
found against both LPS and IFN‐γ induced RAW 264.7 macrophage and N11 microglial cell line.  
The monomeric phloroglucinol derivatives,  compound 6.1  and 6.2  contains  isobutylene  and butylene 
group at position 6 respectively in the structure (Figure 6‐2). Compound 6.1 is found to be several folds 
more  active  regarding  NO  and  TNF‐α  inhibition  in  both  cell  lines  as  compared  to  compound  6.2 
indicating that the double bond of isobutylene is important for better activity of the compound (6.1). 
Compound 6.3  is reported  from several myrtaceous plants and also  from other plant  families  [10‐12]. 
This compound  is commonly known as sideroxylin and has been reported to exhibit antimicrobial [13] 





activity as  found against both  LPS and  IFN‐γ  induced RAW 264.7 macrophage and N11 microglial  cell 
line. 
There  is only one  report on  compound 6.5,  isolated  from  fresh  leaves of  Luma  chequen  (Myrtaceae) 
where this compound has been tested for  its antifeedant and fungistatic activity as well as toxicity [5]. 





NO  in  both  cell  line  and  TNF‐α  in  N11  microglia  compared  to  compound  6.4  indicating  that  the 

































n‐Hexane  135.14  31.17  809.46  186.72  n‐Hexane 
Dichloromethane  130.89  30.67  760.47  178.17  Dichloromethane 
Ethyl acetate  211.86  41.56  750.00  147.13  Ethyl acetate 
Ethanol  62.89  5.63  444.03  39.75  Ethanol 
Methanol  13.52  3.68  34.21  9.32  Methanol 
Water  14.17  4.81  51.16  17.35  Water 





















Compound 6.1  255.75  59.17  2.56  0.59 
Tetragocarbon B 
(6.2)  28.45  31.13  0.07  0.07 
Sideroxylin (6.3)  362.32  48.08  1.09  0.14 
Compound 6.4  33.99  26.62  0.11  0.09 
Lumaflavanone A 






The potency  (for NO and TNF‐α  inhibition) of each of the sequential extracts and  isolated compounds 
from S. glomulifera subsp. glomulifera leaves were measured as a reciprocal of IC50 value (Table 6‐7 and 



















Acetonitrile,  n‐hexane,  dichloromethane  and methanol were  supplied  by Merck.  Ethyl  acetate  from 
Fisher Chemical, ethanol from Chem‐Supply and water used was Milli‐Q water. Bovine serum albumin, 
lipopolysaccharide  (E.  coli  serotype‐0127:B8),  EDTA,  N‐(1‐napthyl)  ethylenediamine  dihydrochloride, 
benzylpenicillin  G  sodium  salt,  resazurin  sodium  salt  (10%),  streptomycin,  sulphanilamide,  3,3′,5,5′‐
tetramethylbenzidine  (TMB),  trypan  blue  and  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  were 
purchased  from  Sigma‐Aldrich  (Castle Hill, NSW, Australia).  Foetal bovine  serum  (FBS)  and  glutamine 
were purchased from Life Technologies (Mulgrave, VIC, Australia). Murine interferon‐γ (IFN‐γ) and TNF‐α 
ELISA  kits  were  purchased  from  PeproTech  Asia  (Rehovot,  Israel).  Citric  acid  and  monosodium 
dihydrogen  carbonate  (NaH2CO3) were  from AJAX Chemicals  (Auburn, NSW, Australia). Tween‐20 was 
from Amresco  (Solon, Ohio, USA). Methanol, monosodium phosphate  (NaH2PO4), disodium phosphate 




spectra were  obtained  on  a  Bruker  Ascend  400 MHz  spectrometer  (Bruker  Biospin  GmbH,  Bremen, 
Germany). TopSpin software was used to analyze the spectral data. 1H NMR spectra were recorded at 
























subjected  directly  through  reversed  phase  semi‐prep  HPLC  (Phenyl‐Hexyl  column,  250  x  10  mm, 








RAW  264.7 macrophages  and  N11 microglial  cells were  grown  in  175  cm2  culture  flasks  on  DMEM 
(Dulbecco’s Modified Eagle’s Medium) containing 5% FBS (fetal bovine serum) that was supplemented 
with  penicillin  (100  units/mL),  streptomycin  (100  μg/mL)  and  glutamine  (2 mM).  The  cell  line  was 
maintained  in  5% CO2  at  37  °C, with media being  replaced  every  3‐4 days. Once  cells had  grown  to 
confluence in the culture flask, they were removed using a rubber policeman cell scraper, as opposed to 
using trypsin, which can remove membrane‐bound receptors. The cell suspension was concentrated by 
centrifugation  for  3 min  at  900  rpm  and  resuspended  in  a  small  volume  of  fresh  DMEM  (with  1% 
antibiotics  and  5%  FBS).  Cell densities were  estimated using  a Neubauer  counting  chamber.  The  cell 
concentration was adjusted with DMEM (with 1% antibiotics and 5% FBS) to obtain 60,000 cells/100 µL 











sequential  extracts  a maximum  dose  of  900  µg/mL  was  used,  and  diluted  serially  by  50%  up  to  a 
minimum of 10 doses  (900, 450, 225, 112.5, 56.25, 28.125, 14.062, 7.031, 3.515, 1.7578 and 0.8789 








Nitric  oxide  was  determined  by  Griess  reagent  quantification  of  nitrite,  one  of  its  stable  reaction 












The  results were expressed as a percentage of  the  intensity of  that  in  control  cells after background 
fluorescence was subtracted. 
6.4.9 TNF‐α determination by ELISA 
The  supernatants  obtained  from  each well  (remaining  supernatant  after  24  hours  of  activation)  and 
experiment that gave better readout for NO and Alamar blue assay were used for determination of TNF‐
α  using  a  commercial  sandwich  ELISA  (Catalog  number:  900‐K54;  Peprotech,  USA)  according  to  the 
manufacturer’s protocol. The supernatants were diluted 30 times using diluent (0.1% w/v bovine serum 
albumin and 0.05% v/v  tween‐20  in PBS  [1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 154 mM NaCl; pH7.4]).  
Capture antibody was used at a concentration of 1.25 μg/mL  in PBS. To make a standard curve TNF‐α 
(10 ng/mL standard) was diluted serially by 50% up to a minimum of 10 doses (10, 5, 2.5, 1.25, 0.625, 
















δC  NMR  data,  see  Table  6.3;  HRESIMS  (pos.):  m/z  [M+Na]






For  sequential extracts,  three experiments  in quadruplicates  (n=12) were combined  to determine  the 
IC50  (for  NO  inhibition)  and  LC50  (for  cell  viability)  whereas  one  experiment  in  triplicate  (n=3)  was 
conducted to obtain  IC50 for   TNF‐α  inhibition using the dose‐response  inhibition function  in GraphPad 
Prism version 6.01 (GraphPad Software Incorporated, USA). For purified compounds, two experiments in 
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Screening of Baeckea ramosissima subsp. 
ramosissima and B. imbricata (Myrtaceae) 






















Baeckea genus  is also  recognized as Euryomyrtus. B.  frutescens L.  is  the most widely studied Baeckea 
species  either  for  chemical  constituents  [4‐7]  or  for  biological  activities  [8,9].  A  broad  range  of 
compounds have been isolated from this Baeckea spp. for example, chromones and chromanones [10], 












IFN‐γ  activated  264.7  RAW  macrophages  and  were  selected  for  investigation  to  identify  bioactive 
compounds. The fresh  leaves of the two plants were then sequentially extracted with n‐hexane, DCM, 
EtOAc, EtOH, MeOH and water. The sequential EtOAc extract from both plants showed the highest anti‐
inflammatory  activity  for NO  inhibition  (IC50  =  9.33  and  8.98  μg/mL  for  Baeckea  ramosissima  subsp. 









































macrophages and N11 microglia.  In RAW 264.7 macrophages, compounds 7.1 and 7.2  showed  strong 




































Fresh  leaves  (230  g)  of  Baeckea  ramosissima  subsp.  ramosissima  (voucher  no.  AD  823136)  and  B. 
imbricata  (120 g)  (voucher no. AC 942545) were  sequentially extracted with  six  solvents  from  low  to 
high polarity which were n‐hexane, DCM, EtOAc, EtOH, MeOH and water in order to separate lipophilic 
from hydrophilic compounds. A variable  range of yields were obtained  from  the extraction  (Table 7‐1 
and 7‐2).  

























The n‐hexane, DCM, EtOAc, EtOH, MeOH and water extracts were  tested  in LPS +  IFN‐γ  induced RAW 
264.7  macrophages  to  obtain  IC50  values  for  NO  and  TNF‐α  down  regulation  and  also  LC50  for 
cytotoxicity. Due to  low solubility of the extracts  in the cell culture media, they were diluted  in DMSO, 
leading to a final concentration of up to 0.5% DMSO in cell culture medium. This concentration of DMSO 
showed a  cell viability of  less  than 10%  (data not  shown). All of  the  sequential extracts with organic 
solvents (n‐hexane, DCM, EtOAc, EtOH and MeOH) demonstrated significant anti‐inflammatory activity 
to down  regulate NO production with  IC50 values  ranging  from   9.3  to 33.0 µg/mL  for B.  ramosissima 
subsp.  ramosissima.  The  sequential  EtOAc  extract  showed highest  activity with  IC50 of  9.33  and 6.96 
µg/mL  for  suppression  of  NO  and  TNF‐α  production  respectively  and  LC50  of  44.99  μg/mL  for  this 
Baeckea spp (Table‐3 and Figure 3). 
On  the  other  hand,  the  sequential  extracts with  organic  solvents  (n‐hexene, DCM,  EtOAc  and  EtOH) 














n‐Hexane  25.21 ± 2.8  27.60 ± 8.2  141.10 ± 50.8 
DCM  13.85 ± 1.5    6.88 ± 2.7  44.18 ± 9.6 
EtOAc    9.33 ± 1.1    6.96 ± 1.8  44.99 ± 9.7 
EtOH  28.65 ± 2.8      33.17 ± 11.49  194.80 ± 42.4 
MeOH  32.82 ± 3.7      86.03 ± 22.26  209.00 ± 74.1 











Figure 7‐4. Down  regulation of  LPS  and  IFN‐γ  induced NO  and  TNF‐α production  and  cell  viability of 



















n‐Hexane  40.40 ± 4.9  65.77 ± 32.9  > 225  89.4 
DCM  13.17 ± 1.6  29.68 ± 14.5  17.03 ± 2.7   
EtOAc  8.98 ± 0.7  8.96 ± 2.7  33.55 ± 4.9   
EtOH  17.64 ± 2.5  57.36 ± 17.5  65.45 ± 9.8   
MeOH   81.27 ± 17.2  57.36 ± 17.5   76.10 ± 19.3   



































































































































































































7.1  10.95 ± 1.7  17.35 ± 4.3  > 36  211.3 
7.2  9.18 ± 1.0  11.26 ± 2.3  > 36  155.5 
 
Brr_7.1_RAW







































Figure 7‐6. Down  regulation of  LPS  and  IFN‐γ  induced NO  and  TNF‐α production  and  cell  viability of 















7.1  19.71 ± 2.0  8.84 ± 1.9  > 36  135.1 




















































































n‐Hexane  39.67  36.23  97.98  89.49 
Dichloromethane  72.20  145.35  325.63  655.52 
Ethyl acetate  107.18  143.68  350.48  469.83 
Ethanol  34.90  30.15  465.62  402.17 
Methanol  30.47  11.62  255.94  97.64 




















Quercetin (7.1)  91.32  57.64  0.26  0.16 












0.33  L were  obtained  by  quercetin  (7.1)  and  kaempferol  (7.2)  respectively.  Similarly,  the  total  anti‐











Acetonitrile,  n‐hexane,  dichloromethane  and methanol were  supplied  by Merck.  Ethyl  acetate  from 
Fisher Chemical, ethanol from Chem‐Supply and water used was Milli‐Q water. Bovine serum albumin, 
lipopolysaccharide  (E.  coli  serotype‐0127:B8),  EDTA,  N‐(1‐napthyl)  ethylenediamine  dihydrochloride, 
benzylpenicillin  G  sodium  salt,  resazurin  sodium  salt  (10%),  streptomycin,  sulphanilamide,  3,3′,5,5′‐
tetramethylbenzidine  (TMB),  trypan  blue  and  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)  were 
purchased  from  Sigma‐Aldrich  (Castle Hill, NSW, Australia).  Foetal bovine  serum  (FBS)  and  glutamine 
were purchased from Life Technologies (Mulgrave, VIC, Australia). Murine interferon‐γ (IFN‐γ) and TNF‐α 
ELISA  kits  were  purchased  from  PeproTech  Asia  (Rehovot,  Israel).  Citric  acid  and  monosodium 
dihydrogen  carbonate  (NaH2CO3) were  from AJAX Chemicals  (Auburn, NSW, Australia). Tween‐20 was 
from Amresco  (Solon, Ohio, USA). Methanol, monosodium phosphate  (NaH2PO4), disodium phosphate 




spectra were  obtained  on  a  Bruker  Ascend  400 MHz  spectrometer  (Bruker  Biospin  GmbH,  Bremen, 
Germany).   TopSpin software was used to analyse the spectral data. 1H NMR spectra were recorded at 
400 MHz.  The  chemical  shifts  (δ)  are  expressed  in  parts  per million  (ppm)  as  δ  values  and  coupling 
constant  J  in  Hertz  (Hz).  The  experiments  were  performed  in  dimethyl  sulfoxide‐d6  (DMSO‐d6)  and 
chemical shifts were calibrated relative to the DMSO solvent peak (1H δ at 2.50 and 13C δ 39.51 ppm). 
High  resolution  mass  spectrometry  (HRMS)  was  carried  out  using  a  Waters  Xevo  Q‐TOF  mass 
spectrometer operating in positive electrospray ionization (ESI) mode. 
7.4.3 Plant material 
Fresh  leaves  of  Baeckea  ramosissima  subsp.  ramosissima  (voucher  no. AD  823136)  and  B.  imbricata 
(voucher  no.  AC  942545)  were  collected  in  the  month  of  July,  2016  from  the  ‘Australian  Botanic 





coarse powder was then  filled  into the thimbles of an accelerated solvent extraction system  (Buchi B‐
811,  Switzerland)  and  extracted  under  standard  Soxhlet mode  (for  2  ×  15 minutes  cycles)  using  six 
solvents  (n‐hexane,  dichloromethane,  ethyl  acetate,  ethanol, methanol  and water)  sequentially  from 
low to high polarity. The volume of the extracts was reduced to ca. 2—4 mL using a rotary evaporator 











from 10% methanol/water  to a 100% methanol  (with a constant 0.01%  formic acid modifier) over 30 
min and held at 100% methanol for 10 min was applied for B.  imbricata. All  isolated compounds were 
purified  to  95%  purity  or more  as  judged  by HPLC  (UV  detection)  and  1H NMR  spectroscopy  before 
determining the bioactivity. 
7.4.5 Maintenance and preparation of RAW 264.7 macrophages and N11 microglia 
RAW  264.7 macrophage  and  N11 microglial  cells  were  grown  in  175  cm2  culture  flasks  on  DMEM 
(Dulbecco’s Modified Eagle’s Medium) containing 5% FBS (fetal bovine serum) that was supplemented 
with  penicillin  (100  u/mL),  streptomycin  (100  μg/mL)  and  glutamine  (2  mM).  The  cell  line  was 
maintained  in  5% CO2  at  37  °C, with media being  replaced  every  3‐4 days. Once  cells had  grown  to 
confluence in the culture flask, they were removed using a rubber policeman cell scraper, as opposed to 
using trypsin, which can remove membrane‐bound receptors. The cell suspension was concentrated by 
centrifugation  for  3 min  at  900  rpm  and  resuspended  in  a  small  volume  of  fresh  DMEM  (with  1% 
antibiotics  and  5%  FBS).  Cell densities were  estimated using  a Neubauer  counting  chamber.  The  cell 
concentration was adjusted with DMEM (with 1% antibiotics and 5% FBS) to obtain 60,000 cells/100 µL 





with extracts, a 90  μL volume of  the dilutions  in DMEM  (with 0.1% FBS) was added an hour prior  to 
addition of the activator. Due to the often inconsistent nature of LPS at activating cells, a combination of 
LPS (10 μg/mL) and IFN‐γ (10 U/mL), both  in DMEM (with 0.1% FBS), were used for activation. For the 





TNF‐α  inhibition,  and  cell  viability were  determined.  Cells with media  alone were  used  as  negative 
control and activated  cells used as positive  control. The effects of  solvents on  readouts were  initially 






Nitric  oxide was  determined  by  Griess  assay  for  quantification  of  nitrite,  one  of  its  stable  reaction 












The  results were expressed as a percentage of  the  intensity of  that  in  control  cells after background 
fluorescence was subtracted. 
7.4.9 TNF‐α determination by ELISA 
The  supernatants  obtained  from  each well  (remaining  supernatant  after  24  hours  of  activation)  and 
experiment that gave better readout for NO and Alamar blue assay were used for determination of TNF‐
α  using  a  commercial  sandwich  ELISA  (Catalog  number:  900‐K54;  Peprotech,  USA)  according  to  the 
manufacturer’s protocol. The supernatants were diluted 30 times using diluent (0.1% w/v bovine serum 
albumin and 0.05% v/v  tween‐20  in PBS  [1.9 mM NaH2PO4, 8.1 mM Na2HPO4, 154 mM NaCl; pH7.4]).  
Capture antibody was used at a concentration of 1.25 μg/mL  in PBS. To make a standard curve TNF‐α 
(10 ng/mL standard) was diluted serially by 50% up to a minimum of 10 doses (10, 5, 2.5, 1.25, 0.625, 




absorbance  was measured  at  450  nm  of measurement  filter  using  a  POLARstar  Omega microplate 
reader  (BMG Labtech, Mornington, Australia). The absorbance data was expressed as a percentage of 
control wells after conversion of the concentrations by using a standard curve constructed with defined 
concentrations of  TNF‐α. Curve  fitting of  this  standard  curve  and  extrapolation of  experimental data 
were performed using non‐linear regression analysis.  
7.4.10 Data presentation and analysis 
For  sequential extracts,  three experiments  in quadruplicates  (n=12) were combined  to determine  the 
IC50  (for  NO  inhibition)  and  LC50  (for  cell  viability)  whereas  one  experiment  in  triplicate  (n=3)  was 
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Persistent  inflammation  contributes  to  multiple  age‐related  chronic  conditions  including 
musculoskeletal  and  neurodegenerative  diseases,  cardiovascular  diseases,  asthma,  rheumatoid 
arthritis  and  inflammatory  bowel  disease.  More  recently,  chronic  neuroinflammation  has  been 
attributed  to  Parkinson’s  and  Alzheimer’s  disease,  autism‐spectrum  and  obsessive‐compulsive 
disorders  [1,2]. Plants having medicinal values are  recognised as  the oldest and most widespread 
form  of medication  throughout  the  world.  On  the  basis  of  ethnobotanical  knowledge  the  anti‐




of  a  total  of  32  plants  for  the  suppression  of  nitric  oxide  and  TNF‐α  production  induced  by 
lipopolysaccharide  (LPS) and  interferon gamma  (IFN‐γ)  in RAW 264.7 macrophages. Cytotoxicity of 
the crude extracts was also examined using an Alamar blue cell viability assay.  
The  plants  studied  here were  chosen  on  the  basis  of  their  traditional  use  to  treat  inflammatory 
conditions  by  the  D’harawal  Aboriginal  people  of  the  Campbelltown  region  (Southwest  Sydney, 
Australia).  Five  of  the  selected  plants  were  fractionated  to  yield  three  new  and  twelve  known 




Aboriginal knowledge as well as preserving the knowledge  for  future generations and at  the same 
time giving additional value to it. 










by humans.  This  could be done with  a  single  compound or  a  combination of  two  compounds or 






















1  Eucalyptus viminalis  44.0 ± 9.0  41.0 ± 23.8  > 36  New 
2  Eucalyptus viminalis 47.0 ± 7.8 38.3 ± 14.8 > 36 Known
3  Eucalyptus viminalis 37.6 ± 4.9 43.2 ± 18.4 > 36 Known
4 (hydrolysed 
product of 1) 
Eucalyptus viminalis 18.7 ± 0.5 21.5 ± 4.4 54.4 ± 21.4 Known
3a.1  Eucalyptus bosistoana  95.74 ± 14.4  51.56 ± 4.6  > 36  Known 
5.1  Melaleuca linariifolia 72.81 ± 37.9 58.88 ± 35.9 > 36 Known
5.2  Melaleuca linariifolia 39.69 ± 11.5 80.70 ± 50.1 > 36 Known
5.3  Melaleuca linariifolia  2.73 ± 0.3  4.11 ± 1.0  9.68 ± 1.1  Known 
6.1  Syncarpia glomulifera subsp. glomulifera  3.91 ± 0.5  16.90 ± 3.4  > 18  New 
6.2  Syncarpia glomulifera subsp. glomulifera  35.15 ± 7.3  32.12 ± 13.2  > 36  Known 
6.3  Syncarpia glomulifera subsp. glomulifera  2.76 ± 0.3  20.80 ± 14.1  > 18  Known 
6.4  Syncarpia glomulifera subsp. glomulifera  29.42 ± 2.7  37.57 ± 11.7  > 36  New 
6.5  Syncarpia glomulifera subsp. glomulifera 7.84 ± 1.3 33.35 ± 3.8 > 36 Known
7.1  Baeckea ramosissima subsp. ramosissima 10.95 ± 1.7 17.35 ± 4.3 > 36 Known






















1  Eucalyptus viminalis  43.4 ± 7.3  20.4 ± 10.5  > 36  New 
2  Eucalyptus viminalis 34.1 ± 4.2 34.3 ± 18.1 > 36 Known
3  Eucalyptus viminalis 21.8 ± 3.7 19.0 ± 7.1 > 36 Known
4 (hydrolysed 
product of 1) 
Eucalyptus viminalis  10.2 ± 1.0  17.0 ± 5.0  > 22.5  Known 
3a.1  Eucalyptus bosistoana 44.31 ± 6.1 35.50 ± 11.3 > 36 Known
5.1  Melaleuca linariifolia 66.27 ± 31.3 17.34 ± 3.3 > 36 Known
5.2  Melaleuca linariifolia  58.05 ± 30.1  21.84 ± 3.6  > 36  Known 
5.3  Melaleuca linariifolia  2.23 ± 0.4  6.76 ± 1.4  11.01 ± 1.4  Known 
6.1  Syncarpia glomulifera subsp. glomulifera  4.52 ± 0.8  6.50 ± 1.3  24.31 ± 6.1  New 
6.2  Syncarpia glomulifera subsp. glomulifera 21.17 ± 3.8 27.01 ± 8.5 > 36 Known
6.3  Syncarpia glomulifera subsp. glomulifera  3.87 ± 0.5  13.66 ± 3.8  19.05 ± 5.7  Known 
6.4  Syncarpia glomulifera subsp. glomulifera  39.64 ± 10.4  33.06 ± 5.9  > 36  New 
6.5  Syncarpia glomulifera subsp. glomulifera  4.51 ± 0.6  5.46 ± 0.7  > 36  Known 
7.1  Baeckea ramosissima subsp. ramosissima  19.71 ± 2.0  8.84 ± 1.9  > 36  Known 
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A new anti-inflammatory chromone from the leaves of Eucalyptus viminalis 
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1  44.00 ± 9.0  40.98 ± 23.8 >36  131.4
2  46.97 ± 7.8  38.27 ± 14.8  >36  145.7 
3  37.61 ± 4.9  43.17 ± 18.4 >36  144.0
4  18.68 ± 0.5  21.48 ± 4.4  54.48 ± 21.4  144.0 
 
Ev_C1_RAW
































1  43.44 ± 7.3  20.37 ± 10.5  >36  136.89 
2  34.10 ± 4.2  34.10 ± 18.1  >36  96.9 
3  21.85 ± 3.7  18.97 ± 7.1  > 36  101.4 








































2  1.84 m  35.6  3  1 
3  3.74 brs  67.1  2, 4 
 
4  4.82 d(4.0)  76.5  5, 3  5 








2’  a7.52 d(8.5)  a129.8  3’  1’, 3’, 4’, 6’, 7’ 





5’  a6.79 d(8.5)  115.6  6’  1’, 3’, 4’ 
6’  a7.52 d(8.5)  a129.8  5’  1’, 2’, 4’, 5’, 7’ 
7’  7.55 (16.0)  144.1  8’  1’, 2’, 6’, 8’, 9’ 






































































Position  δH, Mult (J in Hz)  δc *  COSY  HMBC 
2  4.47 d(7.4)  81.6  3  3, 9, 1’, 2’, 5’ 6’,  















2’  6.72 d(1.8)  115.1  2, 1’, 3’, 4’, 6’ 
3’  ‐  145.0 
4’  ‐  145.0 
5’  6.68 d(8.0)  115.6  6’  2’, 1’, 3’, 4’, 6’ 


































































Position  δH, Mult (J in Hz)  δc *  COSY  HMBC 
2  4.72 s  77.8  3  4, 9, 1’, 2’, 6’ 



















4’  6.88 d(2.4)  118.0  1’, 3’, 5’, 6’ 
5’  ‐  144.8 
























































































Position  δH, Mult (J in Hz)  δC*  COSY  HMBC 
1  1.52 m  a37.7  2  3, 5,  9, 10 
2  a1.80 m  29.0 1, 3 1, 3, 5, 9 
3  a2.96 m  76.5  2  1, 2, 5, 23, 24 
4  ‐‐‐‐  39.1  ‐‐‐‐  ‐‐‐‐ 
5  0.65 m  54.7  6  1, 3, 4, 6, 7, 10, 25 
6  1.31 m  18.0  5, 7  5, 7 
7  1.42 m  a37.7  6  5, 6, 8, 26 
8  ‐‐‐‐  40.8  ‐‐‐‐  ‐‐‐‐ 
9  1.23 m  49.8 11 1, 8, 10, 11, 12, 25 
10  ‐‐‐‐  37.4  ‐‐‐‐  ‐‐‐‐ 
11  1.38 m  20.7  9, 12  9, 12 
12  1.08 m  28.0  11, 13  9, 11, 13, 14 
13  1.22 m  37.5 12, 18 12, 14, 18, 26, 27 
14  ‐‐‐‐  42.5  ‐‐‐‐  ‐‐‐‐ 
15  1.34 m  28.3  16  14, 16, 17, 18, 27, 28 
16  2.1 m  31.5  15  14, 15, 17, 18, 28 
17  ‐‐‐‐  55.4 ‐‐‐‐ ‐‐‐‐ 
18  1.52 m  48.8  13, 19  13, 15, 16, 17, 19, 20, 21, 28 
19  a2.96 m  46.6  18, 21  13, 18, 20, 21, 22, 29, 30 
20  ‐‐‐‐  150.7  ‐‐‐‐  ‐‐‐‐ 
21  a1.80 m  30.4  19, 22  17, 18,  19, 20, 22, 28, 30 
22  1.54 m  37.7  21  17, 19, 20, 21, 28 
23  a0.88 s  a28.0  ‐‐‐‐  3, 4, 5 
24  a0.88 s  a15.7 ‐‐‐‐ 3, 4, 5 
25  0.65 s  a15.7  ‐‐‐‐  1, 5, 9, 10, 14 
26  0.76 s  a15.7 ‐‐‐‐ 7, 10, 13, 27 
27  0.94 s  14.0  ‐‐‐‐  8, 13, 14, 15, 26 
28  ‐‐‐‐  177.5 ‐‐‐‐ ‐‐‐‐ 
29  4.68, 4.56 s  110.2    19, 20, 30 





















































































































3  5.36 s  79.0  1, 2, 4, 5, 7, 8, 9, 10, 11 
4  ‐  39.5 
5  5.22 s  79.7  1, 3, 4, 6, 9, 10, 1’, 1” 
6  ‐  79.5 
7  1.15 s  21.8  1, 2, 3, 8 
8  1.33 s  27.3  1, 2, 3, 7 
9  0.96 s  21.0  3, 4, 5, 10 
10  1.00 s  24.0  3, 4, 5, 9 
11  ‐  170.8 
12  2.11 s  20.6  3, 11 
1’  ‐  165.9 
2’  6.52 d(16.0)  116.9  3’  1’, 3’, 4’ 
3’  7.78 d(16.0)  146.3  2’  1’, 2’, 4’, 5’, 9’ 
4’  ‐  134.2 
5’  a7.56 m  128.5  6’  3’, 4’, 6’, 7’, 9’ 
6’  a7.39 m  128.8  5’, 7’  5’, 7’, 8’,  
7’  a7.56 m  130.6  6’, 8’  5’, 6’, 8’, 9’ 
8’  a7.39 m  128.8  7’, 9’  4’, 5’, 6’, 7’, 9’,  
9’  a7.56 m  128.5  8’  3’, 4’, 5’, 7’, 8’ 





3”  a0.88 dd(6.8, 8.0)  24.8  2”  1”, 2”, 4” 







































































































2’  7.97 d(8.9)  128.0  3’  2, 4’, 6’ 





5’  6.96 d(8.9)  116.0  6’  2, 1’, 4’ 


























































































































































2 5.62 dd(17.1, 2.7) 78.6 3 3, 4, 1’, 2’, 6’
3 3.39 d(3.7), 2.86 dd(13.6, 















16 1.31 s 23.3 13, 14, 15, 17
17 1.23 s 24.5 13, 14, 15, 16
18 1.56 s 24.8 11, 12, 13, 19
19 1.41 s 24.1 11, 12, 13, 18
20 2.14 s 6.6 5, 6, 7 
1’ ‐‐ 138.4
2’ 7.56 dd(8.6, 2.0) 126.0 3’ 2, 6’, 3’ 
3’ 7.48 m 128.3 2’, 4’ 1’, 2’, 4’, 5’
4’ 7.44 m 128.3 3’, 5’ 2’, 3’, 5’, 6’
5’ 7.48 m 128.3 4’, 6’ 1’, 2’, 3’, 4’
6’ 7.56 dd(8.6, 2.0) 126.0 5’ 2, 2’, 5’ 
1” 1.84 m 34.3 2”, 3”, 9 9, 2”, 3” 
2” 0.69 d(7.0) 18.4 1” 9, 1”, 3” 
3” 0.79 d(7.0) 19.1 1” 9, 1”, 2” 
C‐5‐OH 12.3 s ‐‐
*Assignments supported by HSQC and HMBC experiments.  
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6.5.c HR‐ESI‐MS of compound 6.5 
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Chapter 7_Supporting Information  
7.1.a  1H NMR spectrum of compound 7.1 (DMSO‐d6, 400 MHz) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3,5,7,4’,5’‐Pentahydroxy flavone 
or Quercetin 
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7.1.b 1H NMR data(DMSO‐d6, 400 MHz) for compound 7.1 
 
Position  δH, Mult (J in Hz) 
6 
6.18 d(2.0) 
8 
6.40 d(2.0) 
2’ 
7.67 d(2.0) 
5’ 
6.88 d(8.5) 
6’ 
7.53 dd(8.5, 2.0) 
 
 
7.1.c HR‐ESI‐MS of compound 7.1 
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7.2.a  1H NMR spectrum of compound 7.2 (DMSO‐d6, 400 MHz) 
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3,5,7,4’‐Tetrahydroxy flavone 
or Kaemferol 
197
7.2.b 1H NMR data(DMSO‐d6, 400 MHz) for compound 7.2 
 
Position  δH, Mult (J in Hz) 
6 
6.18 d(2.0) 
8 
6.43 d(2.0) 
2’ 
8.04 d(9.0) 
3’ 
6.92 d(9.0) 
5’ 
6.92 d(9.0) 
6’ 
8.04 d(9.0) 
 
 
7.2.c HR‐ESI‐MS of compound 7.2 
 
